Pharmacological actions of the atypical antipsychotic drug clozapine: A review

Synapse

Volumn 24, Issue 4, 1996, Pages 349-394

  Ashby Jr , Charles R ^a   Wang, Rex Y ^b  

^a ST JOHN'S UNIVERSITY   (United States)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

Atypical antipsychotics; Clozapine; Neurotransmitters; Receptors

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; ALPHA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR; CLOZAPINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; GLUTAMATE RECEPTOR; HISTAMINE RECEPTOR; MUSCARINIC RECEPTOR; NEUROLEPTIC AGENT; OLANZAPINE; RADIOLIGAND; SEROTONIN 1A RECEPTOR; SEROTONIN 1C RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN 3 RECEPTOR;

ANIMAL CELL; DRUG EFFICACY; DRUG MECHANISM; HUMAN; HUMAN CELL; MICRODIALYSIS; MONOAMINE METABOLISM; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; POTENTIOMETRY; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; PSYCHOSIS; RECEPTOR AFFINITY; REVIEW; SCHIZOPHRENIA;

ANIMALS; CLOZAPINE; HUMANS; PSYCHOTIC DISORDERS;

EID: 10544244163     PISSN: 08874476     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2396(199612)24:4<349::AID-SYN5>3.0.CO;2-D     Document Type: Review

References (551)

1. Ackenheil, M. (1974) Effect of clozapine on 5-HIAA excretion in urine and CSF of psychotic patients and on tryptophan metabolism in rat brain. International Meeting on Tryptophan Metabolism, Padua.
2. Ackenheil, M., Blatt, B., and Lampert, C. (1975) Effect of clozapine on 5-HIAA excretion in urine and CSF of psychotic patients and on serotonin metabolism in rat brain. Acta Vitam. Enzymol., 29:79-84.
3. Alberch, J., Arenas, J., Perez-Navarro, E., and Marsal, J. (1994) Control of tachykinin-evoked acetylcholine release from rat striatal slices by dopaminergic neurons. Naunyn Schmiedebergs Arch. Pharmacol., 348:445-449.
4. Allikimets, L.H., Zarkovsky, A.M., and Nurk, A.M. (1981) Changes in catalepsy and receptor sensitivity following chronic neuroleptic treatment. Eur. J. Pharmacol., 75:145-147.
5. Al-Shabibi, U.M.H., and Doggett, N.S. (1980) Clozapine's anti-acetylcholine property modulates its antistereotypic action in the mesolimbic system. J. Pharm. Pharmacol., 32:359-361.
6. 2 receptors: An autoradiographic analysis in rat brain. Brain Res. Bull., 16:517-525.
7. Altar, C.A., Boyar, W.C., Wesley, A., Gerhardt, S.C., Liebman, J.M., and Wood, P.L. (1988) Dopamine neurochemical profile of atypical antipsychotics resembles that of D-1 antagonists. Naunyn Schmiedebergs Arch. Pharmacol., 338:162-168.
8. Anchus, A.P., and Pickel, V.M. (1992) Quantitative light microscopic demonstration of increased pallidal and striatal met5-enkephalin-like immunoreactivity in rats following chronic treatment with haloperidol but not with clozapine: Implications for the pathogenesis of neuroleptic-induced movement disorders. Exp. Neurol., 117:17-27.
9. Anden, N.E., and Stock, G. (1973) Effect of clozapine on the turnover of dopamine in the corpus striatum and in the limbic system. J. Pharm. Pharmacol., 25:346-348.
10. Andersen, P.H., and Braestrup, C. (1986) Evidence for different states of the dopamine D1 receptor: Clozapine and fluperlapine may preferentially label and adenylate cyclase-coupled state of the D1 receptor. J. Neurochem., 47:1822-1831.
11. 3H] SCH 23390 binding in vivo. Eur. J. Pharmacol., 120:143-144.
12. Anderson, G.D., and Rebec, G.V. (1983) Clozapine and haloperidol in the amygdaloid complex: Differential effects on dopamine transmission with long-term treatment. Biol. Psychiatry, 23:497-506.
13. Anderson, G.D., and Rebec, G.V. (1986) Differential response of amygdaloid neurons to clozapine and haloperidol: Effects of repeated administration. Pharmacol. Biochem. Behav., 24:1561-1566.
14. 2 receptors in the human neostriatum. Schizophr. Bull., 14:471-484.
15. 2 receptors in rat cerebral cortex. J. Neurochem., 46:187-191.
16. Angulo, J.A., Cadet, J.L., Woolley, C.S., Suber, F., and McEwen, B.S. (1990) The effect of chronic typical and atypical neuroleptic treatment on proenkephalin mRNA levels in the striatum and nucleus accumbens of the rat. J. Neurochem., 54:1889-1894.
17. Arnt, J., Hyttel, J., and Bach-Lauritsen, T. (1986) Further studies of the mechanisms behind scopolamine-induced reversal of antistereotypic and cataleptogenic effects of neuroleptics in rats. Acta Pharmacol. Toxicol., 59:324.
18. Asghari, V., Schools, O., Van Kats, S., Ohara, K., Jovanovic, V., Guan, H.C., Bunzow, J.R., Petronis, A., and Van Tol, H.H.M. (1994) Dopamine D4 receptor repeat: Analysis of different native and mutant forms of the human and rat genes. J. Pharmacol. Exp. Ther., 46:364-373.
19. 4 receptor variants. J. Neurochem., 65:1157-1165.
20. Ashby, C.R., Jr., Edwards, E., Harkins, K.L., and Wang, R.Y. (1989a) Differential effect of typical and atypical antipsychotic drugs on the suppressant action of 2-methylserotonin on medial prefrontal cortical cells: A microiontophoretic study. Eur. J. Pharmacol., 166:583-584.
21. 2-dopamine receptor sensitivity in the rat. Brain Res., 493:194-197.
22. 2 receptors in the medial prefrontal cortex: Microiontophoretic studies. Brain Res., 506:346-348.
23. Ashby, C.R., Jr., Minabe, Y., Edwards, E., and Wang, R.Y. (1991) Comparison of the effects of various typical and atypical antipsychotic drugs on the suppressant action of 2-methylserotonin on medial prefrontal cortical cells in the rat. Synapse, 8:155-161.
24. 3H]YM-09151-2 binding in the rat brain by thioridazine, risperidone and clozapine, but not by other antipsychotics. Eur. J. Pharmacol., 237:183-189.
25. Bakshi, V.P., Swerdlow, N.R., and Geyer, M.A. (1994) Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response. J. Pharmacol. Exp. Ther., 271:787-794.
26. Baldessarini, R.J., and Frankenburg, F.R. (1991) Clozapine. A novel antipsychotic agent. N. Engl. J. Med., 324:746-754.
27. Baldessarini, R.J., and Tarsy, D. (1980) Dopamine and the pathophysiology of dyskinesias induced by antipsychotic drugs. Annu. Rev. Neurosci., 3:23-41.
28. Baldessarini, R.J., Huston-Lyons, D., Campbell, A., Marsh, E., and Cohen, B.M. (1992) Do central antiadrenergic actions contribute to the atypical properties of clozapine? Br. J. Psychiatry [Suppl.], 160:12-16.
29. Bannerjee, S.P., Zuck, L.G., Yablonsky-Alter, E., and Lidksy, T.I. (1995) Glutamate agonist activity: Implications for antipsychotic drug action and schizophrenia. Neuroreport, 6:2500-2504.
30. Bardgett, M.E., Wrona, C.T., Newcomer, J.W., and Csernansky, J.G. (1993) Subcortical excitatory amino acid levels after acute and subchronic administration of typical and atypical neuroleptics. Eur. J. Pharmacol., 230:245-250.
31. 3H]-(S)-zacopride in the forebrain of the rat. Neuropharmacology, 29:1037-1045.
32. Barone, D., Corisco, N., Diena, A., Restelli, A., Glasser, A., and Rodenghi, F. (1982) Biochemical and pharmacological activities of zetidoline (DL308-IT): A new antidopaminergic agent. J. Pharm. Pharmacol., 34:129-132.
33. Bartholini, G. (1976) Differential effect of neuroleptic drugs on dopamine turnover in the extrapyramidal and limbic system. J. Pharm. Pharmacol., 28:429-433.
34. Bartholini, G., Haefely, W., Jalfre, M., Keller, H.H., and Pletscher, A. (1972) Effects of clozapine on cerebral catecholaminergic neurone systems. Br. J. Pharmacol., 46:736-740.
35. Bartholini, G., Keller, H.H., and Pletscher, A. (1973) Effects of neuroleptics on endogenous norepinephrine in the brain. Neuropharmacology, 12:751-756.
36. Bartholini, G., Keller, H.H., and Pletscher, A. (1975) Drug-induced changes of dopamine turnover in striatum and mesolimbic system of the rat. J. Pharm. Pharmacol., 27:439-443.
37. Baskys, A., Wang, S., Remington, G., and Wojtowicz, J.M. (1993) Haloperidol and loxapine but not clozapine increase synaptic responses in the hippocampus. Eur. J. Pharmacol., 235:305-307.
38. 3H]acetylcholine in rat striatal slices: An experimental model for drugs that enhance dopaminergic neurotransmission. J. Neurochem., 44:331-337.
39. Beart, P.M., McDonald, D., and Gundlach, A.L. (1979) Mesolimbic dopaminergic neurons and somatodendritic mechanisms. Neurosci. Lett., 15:165-170.
40. Beasley, C.M., Jr., Tollefson, G., Tran, P., Satterlee, W., Sanger, P., and Hamilton, S. (1996) Olanzapine versus placebo and haloperdiol: Acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology, 14:111-123.
41. Benavides, J., Rumigny, J.F., Bourguignon, J.J., Cash, C., Wermuth, C.G., Mandel, P., Vincendon, G., and Maitre, M. (1982) High affinity site for gamma-hydroxybutyric acid in rat brain. Life Sci., 30:953-961.
42. Beneviste, H. (1989) Brain microdialysis. J. Neurochem., 52: 1667-1679.
43. 3 uptake. J. Neurochem., 62:1112-1118.
44. 2 receptor blocking agent. Curr. Ther. Res., 40:492-499.
45. Blaha, C.D., and Lane, R.F. (1987) Chronic treatment with classical and atypical antipsychotic drugs differentially decreases dopamine release in striatum and nucleus accumbens in vivo. Neurosci. Lett., 78:199-204.
46. Blakely, R.D., Wages, S.A., Justice, J.B., Herndon, J.G., and Neill, D.B. (1984) Neuroleptics increase striatal catecholamine metabolites but not ascorbic acid in dialyzed perfusate. Brain Res., 308:1-8.
47. Blumberg, J.B., Vetulani, R.J., Stawarz, R.J., and Sulser, F. (1976) The noradrenergic cyclic AMP generating system in the limbic forebrain: Pharmacological characterization in vitro and possible role of limbic noradrenergic mechanisms in the mode of action of antipsychotic drugs. Eur. J. Pharmacol., 37:357-366.
48. Bogarts, B. (1993) Recent advances in the neuropathology of schizophrenia. Schizophr. Bull., 19:431-445.
49. 3 binding sites in the rat cerebral cortex and NG 10815 clonal cells. Biochem. Pharmacol., 40:1541-1550.
50. Bolden, B., Cusack, B., and Richelson, E. (1991) Clozapine is a potent and selective muscarinic acetylcholine receptor expressed in CHO-K1 cells. Eur. J. Pharmacol., 192:205-206.
51. Bolden, B., Cusack, B., and Richelson, E. (1992) Antagonism by antimuscarinic and neuroleptic compounds at five cloned human muscarinic cholinergic receptors expressed in Chinese hamster ovary cells. J. Pharmacol. Exp. Ther., 260:576-580.
52. Bolden-Watson, C., Watson, M.A., Murray, K.D., Isackson, P.J., and Richelson, E. (1993) Haloperidol but not clozapine increases neurotensin receptor mRNA levels in rat substantia nigra. J. Neurochem., 61:1141-1143.
53. Borison, R.L., and Diamond, B.I. (1983) Regional selectivity of neuroleptic drugs: An argument for site specificity. Brain Res. Bull., 11:215-218.
54. Bourdelais, A., and Deutch, A.Y. (1994) The effect of haloperidol and clozapine on extracellular GABA levels in the prefrontal cortex of the rat. Cereb. Cortex, 4:69-77.
55. 2 receptor mRNA. Brain Res., 564: 203-219.
56. Bowers, M.B., Jr., (1984) Homovanillic acid in caudate and pre-frontal cortex following neuroleptics. Eur. J. Pharmacol., 99:103-105.
57. Bowers, M.B. Jr., and Rozitis, A. (1974) Regional differences in homovanillic acid concentrations after acute and chronic administration of antipsychotic drugs. J. Pharm. Pharmacol., 26:743-745.
58. Bowers, M.B., Jr., and Rozitis, A. (1976) Brain homovanillic acid: Regional changes over time with antipsychotic drugs. Eur. J. Pharmacol., 39:109-115.
59. Bowers, M.B., Jr., and Rozitis, A. (1977) Brain homovanillic acid: Regional changes following chronic antipsychotic drugs administration. Adv. Biochem. Psychopharmacol., 16:639-644.
60. Bowery, B., Rothwell, L.A., and Seabrook, G.R. (1994) The pharmacology of dopamine receptors mediating the inhibition of cell firing in rat brain slices through the substantia nigra pars compacta and ventral tegmental area. Br. J. Pharmacol., 112:873-880.
61. 2 dopamine and muscarinic receptors in rat striatum. J. Pharmacol. Exp. Ther., 244:987-993.
62. Braestrup, C., and Nielsen, M. (1976) Regulation in the central norepinephrine neurotransmission induced by α-adrenoceptor active drugs. J. Pharmacol. Exp. Ther., 198:596-602.
63. Brann, M.R., Buckley, N.J., and Bonner, T.I. (1988) The striatum and cerebral cortex express different muscarinic receptor mRNA's. FEBS Lett., 230:90-94.
64. Brier, A. (1994) Clozapine and noradrenergic function: Support for a novel hypothesis for superior efficacy. J. Clin. Psychiatry [Suppl], 55:122-125.
65. Brier, A., Buchanan, R.W., Waltrip, R.W., Listwak, S., Holmes, C., and Goldstein, D.S. (1994) The effect of clozapine on plasma norepinephrine: Relationship to clinical efficacy. Neuropsychopharmacology, 10:1-7.
66. Bruhwyler, J., Liegeios, J.F., Chleide, E., Register, F., Damas, J., Delarge, J., and Mercier, M. (1992) Comparative study of typical neuroleptics and clozapine and newly synthesized clozapine-analogues: Correlations between neurochemistry and behaviour. Behav. Pharmacol., 3:567-579.
67. 3 receptor mRNA levels. Neuropharmacology, 23:901-907.
68. Bull, D.R., and Sheehan, M.J. (1991) Presynaptic regulation of electrically evoked dopamine overflow in nucleus accumbens: A pharmacological study using fast cyclic voltammetry in vitro. Naunyn Schmiedebergs Arch. Pharmacol., 343:260-265.
69. Bunney, B.S. (1979) The electrophysiological pharmacology of midbrain dopaminergic systems. In: The Neurobiology of Dopamine. A Horn, J. Korf, and B.H.C. Westerink, eds. Academic Press, London, pp. 417-452.
70. Bunney, B.S., and Aghajanian, G.K. (1974) Central dopaminergic neurons: A model for predicting the efficacy of putative antipsychotic drugs? In: Use of Model Systems in Biological Psychiatry. D. Ingle, ed. MIT Press, Cambridge, pp
71. Bunney, B.S., and Aghajanian, G.K. (1975) Antipsychotic drugs and central dopaminergic neurons: A model for predicting therapeutic efficacy and incidence of extrapyramidal side effects. In: Predictability in Psychopharmacology: Preclincial and Clinical Correlations. A. Sudilovsky, S. Gershon, and B. Beer, eds. Raven Press, New York, pp. 225-245.
72. Bunney, B.S., and Grace, A.A. (1978) Acute and chronic haloperidol treatment: Comparison of effect on nigral dopaminergic activity. Life Sci., 23:1715-1728.
73. 3H-haloperidol binding in the striatum and brain amine metabolism in the rat after treatment with neuroleptics. Life Sci., 23:437-442.
74. Burki, H.R. (1986a) Effects of fluperlapine on dopaminergic systems in rat brain. Psychopharmacology (Berlin), 89:77-89.
75. Burki, H.R. (1986b) Binding of psychoactive drugs to rat brain amine receptors, measured ex vivo, and their effects on metabolism of biogenic amines. Naunyn Schmiedebergs Arch. Pharmacol., 332:258-266.
76. Burki, H.R., Ruch, W., Asper, H., Baggiolini, M., and Stille, G. (1974) Effect of single and repeated administration of clozapine on the metabolism of dopamine and noradrenaline of the rat. Eur. J. Pharmacol., 27:180-190.
77. Burki, H.H., Ruch, W., and Asper, H. (1975) Effects of clozapine, thioridazine, perlapine and haloperidol on the metabolism of the biogenic amines in the brain of the rat. Psychopharmacologia (Berlin), 41:27-33.
78. Burki, H.R., Alder, J., and Eichenberger, E. (1985) Effect of fluperlapine on dopaminergic mechanisms in rat brain. Pharmacopsychiatry, 18:71-72.
79. 125I](R)-trans-7-hydroxy-2[N-propyl-N-(3′-iodo-2′- propenyl) amino]tetralin binding to dopamine D3 receptors in rat olfactory tubercle. J. Pharmacol. Exp. Ther., 268:935-942.
80. Bylund, D.B. (1985) Heterogeneity of alpha-2 adrenergic receptors. Pharmacol. Biochem. Behav., 22:835-843.
81. Bylund, D.B., Eikenberg, D.C., Hieble, J.P., Langer, S.Z., Lefkowitz, R.J., Minneman, K.P., Molinoff, P.B., Ruffolo, R.R., Jr., and Trendelenberg, U. (1994) IV. International Union of Pharmacology nomenclature of adrenoreceptors. Pharmacol. Rev., 46:121-136.
82. Bymaster, F.P., Calligaro, D.O., Falcone, J.F., Marsh, R.D., Moore, N.A., Tye, N.C., Seeman, P., and Wong, D.T. (1996) Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology, 14:87-96.
83. Campbell, A., Yeghiayan, S., Baidessarini, R.J., and Neumeyer, J.L. (1991) Selective antidopaminergic effects of S(+)N-n-propylnoraporphines in limbic versus extrapyramidal sites in rat brain: Comparisons with typical and atypical antipsychotic agents. Psychopharmacology (Berlin), 103:323-329.
84. 1C sites. Eur. J. Pharmacol., 191:93-96.
85. 2A receptor-mediated phosphoinositide (PI) turnover by clozapine in the rat: A comparison to other antipsychotics. Neurosci. Lett., 181:65-68.
86. Casey, D.E. (1989) Clozapine: Neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacology (Berlin), 99:47-53.
87. Casey, D.E. (1991a) Extrapyramidal symptoms in non-human primates: Typical and atypical neuroleptics. Psychopharmacol. Bull., 27:47-50.
88. Casey, D.E. (1991b) Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia. Schizophr. Res., 4:109-121.
89. Casey, D.E. (1993) Serotonergic and dopaminergic aspects of neuroleptic-induced extrapyramidal syndromes in nonhuman primates. Psychopharmacology (Berlin), 112:55-59.
90. Cawley, T.A., Jr., Shickley, T.J., Ruggieri, M.R., and Luthin, G.R. (1993) Effect of chronic neuroleptic treatment on central and peripheral muscarinic receptors. J. Pharmacol. Exp. Ther., 267:134-139.
91. Ceulemans, D., Gelders, Y., Hoppenbrouwers, M.L., and Reyntjens, A. (1984) Does serotonin blockade compensate for dopamine insufficiency in extrapyramidal symptoms? Coll. Int. Neuropsychopharmol. Cong., 14:309.
92. 4 receptors. J. Neurochem., 63:62-65.
93. Chai, B., and Meltzer, H.Y. (1992) The effect of chronic clozapine on basal dopamine release and apomorphine-induced DA release in the striatum and nucleus accumbens as measured by in vivo brain microdialysis. Neurosci. Lett., 136:47-50.
94. Chang, W.-H., Chen, T.-Y., Wu, H.-S., Hu, W.-H., and Yeh, E.-K. (1988) Dose-response curves of homovanillic acid in prefrontal cortex and caudate following antipsychotic drugs: Relation to clinical potencies. Psychopharmacotogy (Berlin), 95:459-462.
95. Chen, J., Paredes, W., and Gardner, E.L. (1991) Chronic treatment with clozapine selectively decreases basal dopamine release in nucleus accumbens but not in caudate-putamen as measured in vivo by brain microdialysis: Further evidence for depolarization block. Neurosci. Lett., 122:127-131.
96. Chen, J., Paredes, W., van Praag, H.M., and Gardner, E.L. (1992a) Serotonin denervation enhances responsiveness of presynaptic dopamine efflux to acute clozapine in nucleus accumbens but not in caudate-putamen. Brain Res., 582:173-179.
97. Chen, J., Ruan, D., Paredes, W., and Gardner, E.L. (1992b) Effects of acute and chronic clozapine on dopaminergic function in the medial prefrontal cortex of awake, freely moving rats. Brain Res., 571:235-241.
98. Cheney, D.L., Zsilla, G., and Costa, E. (1977) Acetylcholine turnover rate in n. accumbens, n. caudatus, globus pallidus and substantia nigra: Action of cataleptogenic and non-cataleptogenic antipsychotics. Adv. Biochem. Psychopharmacol., 16:179-186.
99. Chio, C.L., Drong, R.F., Riley, D.T., Gill, G.S., Slightom, J.L., and Huff, R.M. (1994) D4 dopamine receptor-mediated signaling events determined in transfected Chinese hamster ovary cells. J. Biol. Chem., 269:11813-11819.
100. Chiodo, L.A., and Bunney, B.S. (1983) Typical and atypical neuroleptics: Differential effects of chronic administration of the activity of A9 and A10 midbrain dopaminergic neurons. J. Neurosci., 3:1607-1619.
101. Chiodo, L.A., and Bunney, B.,S. (1985) Possible mechanisms by which repeated clozapine administration differentially affects the activity of two subpopulations of midbrain dopamine neurons. J. Neurosci., 5:2539-2544.
102. Christian, H., Andrea, K.G., Bernhard, A., Hans-Gunther, K., Christian, H., Elvar, T., and Aloig, S. (1990) Effects of haloperidol and clozapine on preprotachykinin-A messenger RNA, tachykinin tissue levels, release, and neurokinin-1 receptor in the striato-nigral system. Synapse, 6:1-9.
103. Cohen, B.M., and Lipinski, J.F. (1986a) Treatment of acute psychosis with non-neuroleptic agents. Psychosomatics, 27:7-16.
104. Cohen, B.M., and Lipinski, J.F. (1986b) In vivo potencies of antipsychotic drugs in blocking alpha1 noradrenergic and dopamine D2 receptors: Implications for drug mechanisms of action. Life Sci., 39:2571-2580.
105. Commissiong, J.W. (1985) Monoamine metabolites: Their relationship and lack of relationship to monoaminergic neuronal activity. Biochem. Pharmacol., 34:1127-1131.
106. Compton, D.R., and Johnson, K.M. (1989) Effects of acute and chronic clozapine and haloperidol on in vitro release of acetylcholine and dopamine from striatum and nucleus accumbens. J. Pharmacol. Exp. Ther., 234:195-203.
107. Conn, P.J., and Sanders-Bush, E. (1985) Serotonin-stimulated phosphoinositide turnover: Mediation by the S2 binding site in rat cerebral cortex but not in subcortical regions. J. Pharmacol. Exp. Ther., 234:195-203.
108. Consolo, S., Ladinsky, H., Bianchi, S., and Ghezzi, D. (1977) Apparent lack of a dopaminergic-cholinergic link in the rat nucleus accumbens and septi-tuberculum olfactorium. Brain Res., 135:255-263.
109. Corbett, R. (1995) Clozapine but not haloperidol antagonizes an MK-801 discriminative stimulus cue. Pharmacol. Biochem. Behav., 51:561-564.
110. Corbett, R., Camacho, F., Woods, A.T., Kerman, L.L., Fishkin, R.J., Brooks, K., and Dunn, R.W. (1995) Antipsychotic agents antagonize non-competitive N-methyl-D-aspartate antagonist-induced behaviors. Psychopharmacology (Berlin), 120:67-74.
111. Costa, E. (1977) Introduction: Morphine, amphetamine and noncataleptogenic neuroleptics. Adv. Biochem. Psychopharmacol., 16: 557-563.
112. Costa, E., Cheney, D.L., Mao, C.C., and Moroni, F. (1978) Action of antischizophrenic drugs on the metabolism of gamma-aminobutyric acid and acetylcholine in globus pallidus, striatum and nucleus accumbens. Fed. Proc., 37:2408-2414.
113. Costall, B., and Naylor, R.J. (1973) Neuroleptic and non-neuroleptic catalepsy. Arzneimittelforschung, 23:674-683.
114. Costall, B., and Naylor, R.J. (1974) The nucleus amygdaloideus centralis and neuroleptic activity in the rat. Eur. J. Pharmacol., 25:138-146.
115. Costall, B., and Naylor, R.J. (1975) The behavioral effects of dopamine applied intracerebrally to areas of the mesolimbic system. Eur. J. Pharmacol., 32:87-94.
116. Costall, B., Naylor, R.J., and Nohria, V. (1979) Hyperactivity response to apomorphine and amphetamine in the mouse: The importance of the nucleus accumbens and caudate-putamen. J. Pharm. Pharmacol., 31:259-266.
117. Cotes, M., Crow, T.J., Johnstone, E.C., Bartlett, W., and Bourne, R.C. (1978) Neuroendocrine change in acute schizophrenia as a function of clinical state and neuroleptic medication. Psychol. Med., 8:657-665.
118. 3H-spiroperidol binding to dopamine receptors in rat striatal membranes: Influence of loxapine and its hydroxylated metabolites. Eur. J. Pharmacol., 55:215-218.
119. Coward, D.M. (1982) Classical and non-classical neuroleptics induce supersensitivity of nigral GABA-ergic mechanisms in the rat. Psychopharmacology (Berlin), 78:180-184.
120. Crane, G.E. (1973) Persistent dyskinesia. Br. J. Psychiatry, 122:395-495.
121. Creese, I., Burt, D.R., and Snyder, S.H. (1976) Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science, 192:481-483.
122. Creese, I., Stewart, K., and Snyder, S.H. (1979) Species variations in dopamine receptor binding. Eur. J. Pharmacol., 60:55-66.
123. Criswell, H.E., Mueller, R.A., and Breese, G.A. (1989) Clozapine antagonism of D-1 and D-2 dopamine receptor mediated behaviors. Eur. J. Pharmacol., 159:141-147.
124. Czyrak, A., Skuza, G., Rogoz, Z., Frankiewcz, T., and Maj, J. (1994) Pharmacological action of zotepine and other antipsychotics on central 5-hydroxytryptamine receptor subtypes. Arzneimittelforschung, 44:113-118.
125. 2 receptor: Two molecular forms generated by alternative slicing. EMBO J., 8:4025-4034.
126. Daly, D.A., and Moghaddam, B. (1993) Actions of clozapine and haloperidol on the extracellular levels of excitatory amino acids in the prefrontal cortex and striatum of conscious rats. Neurosci. Lett., 152:61-64.
127. 2-like" agonist, RU 24213. Br. J. Pharmacol., 113:839-844.
128. Da Silva, S. (1987) Does brain 3,4-dihydroxyphenylacetic acid (DOPAC) reflect dopamine release? J. Pharm. Pharmacol., 39:127-129.
129. Da Silva, S. (1990) A kinetic study of the rats of formation of dopamine, 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) in the rat brain: Implications for the origin of DOPAC. Neuropharmacology, 29:869-874.
130. Davis, D.A., de Paulis, T., Janowsky, A., and Smith, H.E. (1990) Chlorosubstituted, sterically hindered 5,11-dicarbo analogues of clozapine as potential chiral antipsychotic agents. J. Med. Chem., 33:809-814.
131. De Belleroche, J.S., and Neal, M.J. (1982) The contrasting effects of neuroleptics on transmitter release from the nucleus accumbens and corpus striatum. Neuropharmacology, 16:385-390.
132. Delfs, J.M., Anegawa, N.J., and Chesselet, M.-F. (1995) Glutamate decarboxylase messenger mRNA in rat pallidum: Comparison of the effects of haloperidol, clozapine and combined haloperidol-scopolamine treatments. Neuroscience, 66:67-80.
133. Deutch, A.Y. (1994) Identification of the neural systems subserving the actions of clozapine: Clues from immediate early gene expression. J. Clin. Psychiatry [Suppl.], 55:37-42.
134. Deutch, A.Y., Lee, M.C., and Iadorola, M.J. (1992) Regionally specific effects of atypical antipsychotic drugs on striatal fos expression: The nucleus accumbens shell as a locus of antipsychotic action. Mol. Cell. Neurosci., 3:332-341.
135. Deutch, A.Y., Ongur, D., and Duman, R.S. (1995) Antipsychotic drugs induce Fos protein in the thalamic paraventricular nucleus: A novel locus of antipsychotic drug action. Neuroscience, 66:337-346.
136. Di Chiara, G. (1990) Brain dialysis of neurotransmitters: A commentary. J. Neurosci. Methods, 34:29-34.
137. Didriksen, M., Olsen, G.M., and Christensen, A.V. (1993) Effect of clozapine upon schedule-induced polydipsia (SIP) resembles neither the actions of dopamine D1 nor D2 receptor blockade. Psychopharmacology (Berlin), 113:250-256.
138. Dorje, F., Levey, A.I., and Brann, M.R. (1992) Immunological detection of muscarinic subtype proteins (m1-m5) in rabbit peripheral tissues. Mol. Pharmacol., 40:459-462.
139. Dragunow, M., Robertson, G.S., Faull, R.L.M., Robertson, H.A., and Jansen, K. (1990) D2 dopamine receptor antagonists induce Fos and related proteins in rat striatal neurons. Neuroscience, 37:287-294.
140. Drew, K.L., O'Connor, W.T., Kehr, J., and Ungerstedt, U. (1990) Regional specific effects of clozapine and haloperidiol on GABA and dopamine release in rat basal ganglia. Eur. J. Pharmacol., 187:385-397.
141. Dubuc, I., Protais, P., Colboc, O., and Costentin, J. (1982) Antagonism of the apomorphine-induced yawning by atypical neuroleptics. Neuropharmacology, 21:1203-1206.
142. 1 receptor? Life Sci., 57:275-283.
143. Egan, M.F., Karoum, F., and Wyatt, R.J. (1991) Effects of acute and chronic clozapine and haloperidol administration on 3-methoxytyramine accumulation in rat prefrontal cortex, nucleus accumbens and striatum. Eur. J. Pharmacol., 199:191-199.
144. Ellenbroek, B.A., and Cools, A.R. (1988) The paw test: An animal model for neuroleptic drugs which fulfills the criteria for pharmacological isomorphism. Life Sci., 42:1205-1213.
145. Ellenbroek, B.A., Peeters, B.W., Honig, W.M., and Cools, A.R. (1987) The paw test: A behavioral paradigm for differentiating between classical and atypical neuroleptic drugs. Psychopharmacology (Berlin), 93:343-348.
146. 2 receptors in the effects of the classical neuroleptic haloperidol and the atypical neuroleptic clozapine. Eur. J. Pharmacol., 196:103-108.
147. Factor, S.A., and Brown, D. (1992) Clozapine prevents recurrence of psychosis in Parkinson's disease. Mov. Disord., 7:125-130.
148. Farber, N.B., Price, M.T., Labruyere, R., Nemnich, J., St. Peter, H., Wozniak, D.F., and Olney, J.W. (1993) Antipsychotic drugs block phencyclidine receptor-mediated neurotoxicity. Biol. Psychiatry, 34:119-121.
149. Farde, L., and Nordstrom, A.L. (1992) PET analysis indicates atypical central dopamine receptor occupancy in clozapine-treated patients. Br. J. Psychiatry, 160:30-33.
150. Farde, L., Wiesel, F.A., Halldin, C., and Sedvall, G. (1988) Central D2 dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch. Gen. Psychiatry, 45:71-78.
151. Farde, L., Wiesel, F.A., Nordstrom, A.-L., and Sedvall, G. (1989) D1- and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics. Psychopharmacology (Berlin), 99:28-31.
152. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Arch. Gen. Psychiatry, 49:538-544.
153. Farde, L., Nordstrom, A.L., Nyberg, S., Halladin, C., and Sedvall, G. (1994) D1-, D2-, and 5-HT2-receptor occupancy in clozapine-treated patients. J. Clin. Psychiatry [Suppl.], 55:67-69.
154. Farde, L., Nordstrom, A.-L., Karlsson, P., Halldin, C., and Sedvall, G. (1995) Positron emission tomography studies on dopamine receptors in schizophrenia. Clin. Neuropharmacol. [Suppl.], 18:121-129.
155. Ferrari-Dileo, G., Waelbroeck, M., Mash, D.C., and Flynn, D.D. (1994) Selective labeling and localization of the M4 (m4) muscarinic receptor subtype. Mol. Pharmacol., 46:1028-1035.
156. Ferre, S., and Artigas, F. (1995) Clozapine decreases serotonin extracellular levels in the nucleus accumbens by a dopamine receptor-independent mechanism. Neurosci. Lett., 187:61-64.
157. Fibiger, H.C. (1994) Neuroanatomical targets of neuroleptic drugs as revealed by Fos immunochemistry. J. Clin. Psychiatry [Suppl.], 55:33-36.
158. Fielding, S., and Lal, H. (1978) Behavioral actions of neuroleptics. In: Neuroleptics and Schizophrenia. L.L. Iversen, S.D. Iversen, and S.H. Snyder, eds. Raven Press, New York, pp. 95-128.
159. Fink-Jensen, A., and Kristensen, P. (1994) Effects of typical and atypical neuroleptics on Fos protein expression in the rat forebrain. Neurosci. Lett., 182:115-118.
160. 2 receptor blockade to haloperidol. Neurosci. Lett., 194:77-80.
161. Fitzgerald, L.W., Deutch, A.Y., Gasic, G., Heinemann, S.F., and Nestler, E.J. (1995) Regulation of cortical and subcortical glutamate receptor subunit expression by antipsychotic drugs. J. Neurosci., 15:2453-2461.
162. 3H-GABA into rat brain synaptosomes. Acta Pharmacol. Toxicol., 42:73-76.
163. Fjalland, B., Christensen, A.V., and Hyttel, J. (1977) Peripheral and central muscarinic receptor affinity of psychotropic drugs. Naunyn Schmiedebergs Arch. Pharmacol., 301:5-9.
164. 4 dopamine receptors in postmortem human brain. Neurosci. Lett., 175:17-20.
165. Frederick, J.A., Lopez, J.F., and Meador-Woodruff, J.H. (1995) Effects of clozapine and haloperidol on expression of 5-HT6 and 5-HT7 receptors. Soc.
166. Freeman, A.S., and Bunney, B.S. (1987) Chronic neuroleptic effects on dopamine neuron activity: A model for predicting therapeutic efficacy and side effects. Psychopharmacol. Ser., 3:225-235.
167. Frey, P., Fuxe, K., Eneroth, P., and Agnati, L.F. (1986) Effects of acute and long-term treatment with neuroleptics on regional telencephalic neurotensin levels in the male rat brain. Neurochem. Int., 8:429-434.
168. Friedman, E., Gianutosos, G., and Kuster, J. (1983) Chronic fluphenazine and clozapine elicit opposite changes in brain muscarinic receptor binding: Implications for understanding tardive dyskinesia. J. Pharmacol. Exp. Ther., 226:7-12.
169. Friedman, J.H., and Lannon, M.C. (1990) Clozapine responsive tremor in Parkinson's disease. Mov. Disord., 5:225-229.
170. 1 dopamine receptors in discrete brain areas of the male rat. Neurosci. Lett., 106:169-174.
171. Gale, K. (1980) Chronic blockade of dopamine receptors by antischizophrenic drugs enhances GABA binding in the substantia nigra. Nature, 283:569-570.
172. Gallagher, D.W., and Aghajanian, G.K. (1976) Effect of antipsychotic drugs on the firing of dorsal raphe cells. I. Role of adrenergic system. Eur. J. Pharmacol., 39:341-355.
173. Gardner, E.L. (1992) Neuroanatomical specificity of action of the atypical antipsychotics: Implications for a new era in the pharmacotherapy of schizophrenia. In: New Biological Vistas on Schizophrenia. J.P. Lindenmayer and S.R. Kay, eds. Brunner/Mazel, New York, pp. 158-181.
174. Gardner, E.L., and Paredes, W. (1992) Clozapine: Anticholinergic basis of its mesolimbic specificity? Clin. Neuropharmacol. [Suppl.], 15:25.
175. Gardner, E.L., and Seeger, T.F. (1983) Neurobehavioral evidence for mesolimbic specificity of action by clozapine: Studies using electrical intracranial self-stimulation. Biol. Psychiatry, 18:1357-1362.
176. Gardner, E.L., and Seeger, T.F. (1988) Anatomically selective action of atypical neuroleptics on the mesocorticolimbic dopamine system. Ann. N.Y. Acad. Sci., 537:479-481.
177. Gardner, E.L., Walker, L.S., and Paredes, W. (1993) Clozapine's functional mesolimbic selectivity is not duplicated by the addition of anticholinergic action to haloperidol: A brain stimulation study in the rat. Psychopharmacology (Berlin), 110:119-124.
178. Gardner, E.L., Chen, J., and Paredes, W. (1994) Clozapine produces potent antidopaminergic effects anatomically specific to the messolimbic system. J.Clin. Psychiatry, 55(9): 15-22.
179. Garrett, M.C., and da Silva, P.S. (1990) Role of type A and B monoamine oxidase on the formation of 3,4-dihydroxyphenylacetic acid (DOPAC) in tissues from the brain of the rat. Neuropharmacology, 29:875-879.
180. 3H]quinpirole binding sites in rat brain. Synapse, 14:113-120.
181. Gellman, R.L., and Aghajanian, G.K. (1994) Serotonin2 receptor-mediated excitation of interneurons in piriform cortex: Antagonism by atypical antipsychotic drugs. Neuroscience, 58:515-525.
182. Gerlach, J., Thorsen, K., and Fog, R. (1975) Extrapyramidal reactions and amino metabolites in cerebrospinal fluid during haloperidol and clozapine treatment of schizophrenic patients. Psychopharmacology (Berlin), 40:341-350.
183. 2/NT receptor balance in the mesostriatal and mesolimbocortical systems after chronic treatment with typical and atypical neuroleptics drugs. Brain Res., 532:140-145.
184. Giardino, L., Calza, L., Piazza, P.V., and Amato, G. (1991) Multiple neurochemical action of clozapine: A quantitative autoradiographic study of DA 2, opiate and benzodiazepine receptors in the rat brain after long-term treatment. J. Neural. Transm., 83:189-203.
185. 2 dopamine receptor isoforms. Nature, 342:923-929.
186. Goldstein, J.M., Litwin, L.C., Sutton, E.B., and Malick, J.B. (1989) Effects of ICI 169,369, a selective serotonin2 antagonist, in electrophysiological tests predictive of antipsychotic activity. J. Pharmacol. Exp. Ther., 249:673-680.
187. Golstein, J.M., Litwin, L.C., Sutton, E.B., and Malick, J.B. (1993) Seroquel: Electrophysiological profile of a potential atypical antipsychotic. Psychopharmacology (Berlin), 112:293-298.
188. Gonon, F. (1988) Nonlinear relationship between impulse flow and dopamine released by rat midbrain dopaminergic neurons as studied by in vivo electrochemistry. Neuroscience, 24:19-28.
189. Grace, A.A. (1992) The depolarization block hypothesis of neuroleptic action: Implications for the etiology and treatment of schizophrenia. J. Neural Transm. [Suppl.], 36:91-131.
190. Grace, A.A., and Bunney, B.S. (1986) Induction of depolarization block in midbrain dopamine neurons by repeated administration of haloperidol: Analysis using in vivo intracellular recording. J. Pharmacol. Exp. Ther., 238:1092-1100.
191. 3 receptor antagonists: A critical update on therapeutic potential. Trends Pharmacol. Sci., 14:265-270.
192. Groppetti A., Parenti, M., Galli, C.L., Bugatti, A., Cattabeni, F., Di Guilio, A.M., and Racagni, G. (1978) 3-methoxytyramine and different neuroleptics: Dissociation from HVA and DOPAC. Life Sci., 23:1763-1768.
193. Groß, G., and Schumann, H.-J. (1980) Enhancement of noradrenaline release from rat cerebral cortex by neuroleptic drugs. Naunyn Schmiedebergs Arch. Pharmacol., 315:103-109.
194. Groß, G., and Schumann, H.-J. (1982) Effect of long term treatment with atypical neuroleptic drugs on beta adrenoceptor binding in rat cerebral cortex and myocardium. Naunyn Schmiedebergs Arch. Pharmacol., 321:271-275.
195. Gross, H., and Langer, E. (1966) Das Wirkungsporfil eines Chemisch Neuratigen Breitbandneuroleptikums der Dibenzodiazepingruppe. Wien. Med. Wochenschr., 116:814-816.
196. Gross, G., Xin, X., and Gastpar, M. (1991) Trimipramine: Pharmacological evaluation and comparison with clozapine. Neuropharmacology, 30:1159-1166.
197. Grotta, J. (1994) Safety and tolerability of the glutamate antagonist CGS 19755 in acute stroke patients. Stroke, 25:255.
198. Gudelsky, G.A., and Meltzer, H.Y. (1989) Activation of tuberoinfundibular dopamine neurons following the acute administration of atypical antipsychotics. Neuropsychopharmacology, 2:45-51.
199. Gudelsky, G.A., Berry, S.A., and Meltzer, H.Y. (1989) Actions of typical and atypical drugs on tuberoinfundibular dopamine neurons. Psychopharmacol. Bull., 25:377-382.
200. Guo, N., and Fibiger, H.C. (1993) Serotonergic and noradrenergic mechanisms do not mediate clozapine-induced increases in c-fos expression in the frontal cortex. Soc. Neurosci. Abstr., 19:382.
201. Guo, N., and Fibiger, H.C. (1994) D3 and D4 receptors mediate clozapine-induced c-fos expression in the forebrain. Soc. Neurosci. Abstr., 20:1638.
202. Guo, N., Klitenick, M.A., Tham, C.-S., and Fibiger, H.C. (1995) Receptor mechanisms mediating clozapine-induced c-fos expression in the forebrain. Neuroscience, 65:747-756.
203. Gygi, S.P., Gibb, J.W., and Hanson, G.R. (1994) Differential effects of antipsychotic and psychotomimetic drugs on neurotensin system of discrete extrapyramidal and limbic regions. J. Pharmacol. Exp. Ther., 270:192-197.
204. Hall, H., Sallemark, M., and Jerning, E. (1986) Effect of remoxepride and some related new substitute salicylamides on rat brain receptors. Acta Pharmacol. Toxicol., 58:61-70.
205. 3H] raclopride to rat and human brain membranes. J. Neurochem., 55:2048-2057.
206. 2-dopamine receptor binding in the post-mortem human brain. An autoradiographic study. Eur. Neuropsychopharmacology, 5:19-25.
207. Haller, E., and Binder, R.L. (1990) Clozapine and seizures. Am. J. Psychiatry, 147:1069-1071.
208. Halperin, R., Jr., Guerin, J.J., and Davis, K.L. (1989) Regional differences in the induction of behavioral supersensitivity by prolonged treatment with atypical neuroleptics. Psychopharmacology (Berlin), 98:386-391.
209. Hand, T.H., Hu, X.-T., and Wang, R.Y. (1987a) Differential effects of acute clozapine and haloperidol on the activity of ventral tegmental area (A10) and nigrostriatal (A9) dopamine neurons. Brain Res., 415:257-269.
210. Hand, T.H., Hu, X.T., and Wang, R.Y. (1987b) Differential effects of typical and atypical antipsychotic drugs on the activity of dopamine neurons and their postsynaptic target cells. In: Neurophysiology of Dopaminergic Systems: Current Status and Clinical Perspectives. L.A. Chiodo and A.S. Freeman, eds. Lakeshore Publishing Co., Detroit, pp. 141-163.
211. Haring, C., Humpel, C., Skofitsch, G., Krobath, J., Javorsky, F., and Sana, A. (1991) Calcitonin gene-related peptide in the amygdaloid complex of the rat: Immunohistochemical and quantitative distribution, and drug effects on calcium dependent, potassium-evoked in vitro release. Synapse, 8:261-269.
212. 11C) clozapine in the brain of rhesus monkey studied by positron emission tomography (PET). Psychopharmacology (Berlin), 89:248-252.
213. 11C-labelled dopamine receptor antagonists in the brain of rhesus monkeys studied with positron emission tomography. Acta Neurol. Scand., 77:314-321.
214. Hauber, W. (1993a) Clozapine improves dizocilpine-induced delayed alteration impairment in rats. J. Neural Transm., 94:223-233.
215. Hauber, W. (1993b) Dizocilpine-induced delayed alteration impairment is improved by clozapine. In: Gene, Brain, Behavior. N. Elsner and M. Heisenberg, eds. Thieme, Stuttgart, p. 691.
216. Haubrich, D.R., Wang, P.L.F., Herman, R.L., and Clody, D.E. (1975) Acetylcholine synthesis in rat brain: Dissimilar effects of clozapine and chlorpromazine. Life Sci., 17:739-748.
217. Hernandez, L., and Hoebel, B.G. (1989) Haloperidol given chronically decreases basal dopamine in the prefrontal cortex more than the striatum or nucleus accumbens as simultaneously measured by microdialysis. Brain Res. Bull., 22:763-769.
218. Hernandez, L., and Hoebel, G.B. (1995) Chronic clozapine selectively decreases prefrontal cortex dopamine as shown by simultaneous cortical, accumbens and striatal microdialysis in freely moving rats. Pharmacol. Biochem. Behav., 52:581-589.
219. Herrling, P.L. (1994) D-CPPene (SDZ EAA 494), a competitive NMDA antagonist: Results from animal models and first results in humans. Neuropsychopharmacology, 10:591.
220. Herrling, P.L., and Misbach-Lesenne, B. (1982) Effects of clozapine in a selective muscarinic bioassay and on single cells in the rat hippocampus. Naunyn Schmiedebergs Arch. Pharmacol., 320:20-25.
221. 2 receptors. J. Pharmacol. Exp. Ther., 263:276-284.
222. Hoffman, D.C. (1992) Typical and atypical neuroleptics antagonize MK-801-induced locomotion and stereotypy in rats. J. Neural Transm., 89:1-10.
223. Hoffman, D.C., and Donovan, H. (1995) Catalepsy as a rodent model for detecting antipsychotic drugs with extrapyramidal side effect liability. Psychopharmacology (Berlin), 120:128-132.
224. Hoffman, D.C., Donovan, H., and Cassella, J.V. (1993) The effect of haloperidol and clozapine on the disruption of sensorimotor gating induced by the noncompetitive glutamate antagonist MK-801. Psychopharmacology (Berlin), 111:339-344.
225. Hong, J.S., Yang, H.-Y.T., Fratta, W., and Costa, E. (1978) Rat striatal methionineenkephalin content after chronic treatment with calateptogenic and noncataleptogenic antischizophrenic drugs. J. Pharmacol. Exp. Ther., 205:141-147.
226. Honma, T., and Fukushima, H. (1978) Effects of bilateral lesions in the striatum or nucleus accumbens on the cataleptogenic activity of neuroleptics in rats. Jpn. J. Pharmacol., 28:231-238.
227. Hornung, R., Presek, P., and Glossman, H. (1979). Alpha adrenoceptors in rat brain: Direct identification with prazosin. Naunym Schmiedebergs Arch. Pharmacol., 308:223-330.
228. 3H-spiroperidol in the striatum and mesolimbic system of the rat in vitro. Life Sci., 23:599-604.
229. 3 recognition sites: Fact or artifact? Eur. J. Pharmacol., 171:137-139.
230. Hu, X-T., and Wang, R.Y. (1989) Haloperidol and clozapine: Differential effects on the sensitivity of caudate-putamen neurons to dopamine agonists and cholecystokinin following one month continuous treatment. Brain Res., 486:325-333.
231. Huff, R.M., and Adams, R.N. (1980) Dopamine release in nucleus accumbens and striatum by clozapine: Simultaneous monitoring by in vivo electrochemistry. Neuropharmacology, 19:587-590.
232. Humpel, C., Knaus, G.A., Auer, B., Knaus, H.G., Haring, C., Theodorsson, E., and Saria, A. (1990) Effects of haloperidol and clozapine on preprotachykinin-A messenger RNA, tachykinin tissue levels, release, and neurokinin-1 receptors in the striatonigral system. Synapse, 6:1-9.
233. 3H-cis(Z)-flupenthixol binding and on adenylate cyclase activity in vitro. Life Sci., 23:551-556.
234. Ichikawa, J., and Meltzer, H.Y. (1990) The effect of chronic clozapine and haloperidol on basal dopamine release and metabolism in rat striatum and nucleus accumbens studied by in vivo microdialysis. Eur. J. Pharmacol., 176:371-374.
235. Ichikawa, J., and Meltzer, H.Y. (1991) Differential effects of repeated treatment with haloperidol and clozapine on dopamine release and metabolism in the striatum and nucleus accumbens. J. Pharmacol. Exp. Ther., 256:348-357.
236. Ichikawa, J., and Meltzer, H.Y. (1992) The effect of chronic atypical antipsychotic drugs and haloperidol on amphetamine-induced dopamine release in vivo. Brain Res., 574:98-104.
237. Imperato, A., and Angelucci, L. (1989) The effects of clozapine and fluperlapine on the in vivo release and metabolism of dopamine in the striatum and in the prefrontal cortex of freely moving rats. Psychopharmacol. Bull., 25:383-389.
238. Invernizzi, R., Morali, F., Pozzi, L., and Samanin, R. (1990) Effects of acute and chronic clozapine on dopamine release and metabolism in the striatum and nucleus accumbens of conscious rats. Br. J. Pharmacol., 100:774-778.
239. Invernizzi, R., Pozzi, R., and Samanin, R. (1995) Further studies on the effects of chronic clozapine on regional extracellular dopamine levels in the brain of conscious animals. Brain Res., 670:165-168.
240. Jackson, D.M., Anden, N.E., and Dahlstrom, A. (1975) A functional effect of dopamine in the nucleus accumbens and in some other dopamine-rich parts of the rat Brain. Psychopharmacology (Berlin), 45:139-149.
241. 3H]MK-801 binding to the glutamate receptor-ion channel complex. Schizophr. Res., 6:189-194.
242. Janowsky, A., Neve, K.A., Kinzie, J.M., Taylor, B., de Paulis, T., and Belknap, J.K. (1992) Extrastriatal dopamine D2 receptors: Distribution, pharmacological characterization and region-specific regulation by clozapine. J. Pharmacol. Exp. Ther., 261:1282-1290.
243. Jaskiw, G.E., Hussain, G., and Meltzer, H.Y. (1993) Frontal cortical lesions modify the cataleptogenic properties of haloperidol but not of clozapine. Biol. Psychiatry, 34:188-190.
244. Jenner, P., and Marsden, C.D. (1987) Chronic pharmacological manipulation of dopamine receptors in the brain. Neuropharmacology, 26:931-940.
245. Jiang, L.H., Kasser, R.J., Altar, C.A., and Wang, R.Y. (1990) One year of continuous treatment with haloperidol or clozapine fails to induce a hypersensitive response of caudate putamen neurons to dopamine D1 and D2 receptor agonists. J. Pharmacol. Exp. Ther., 253:1198-1205.
246. Johansson, C., Jackson, D.M., and Svensson, L. (1994) The atypical antipsychotic, remoxipride, blocks phencyclidine-induced disruption of prepulse inhibition in the rat. Psychopharmacology (Berlin), 116:437-442.
247. Justice, J.B., Jr., (1987) Introduction to in vivo voltammetry. In: Voltammetry in the Neurosciences: Principles, Methods and Applications. J.B. Justice, Jr., ed. Humana Press, Clifton, New Jersey, pp. 3-102.
248. Kaakola, S., Mannisto, P.T., and Nissinen, E. (1987) Striatal membrane-bound and soluble catechol-O-methyl-transferase after selective neuronal lesions in the rat. J. Neural Transm. 69:221-228.
249. Kane, J., Honigfeld, G., Singer, J., Meltzer, H.Y., and the Clozaril Collaborative Study Group (1988) Clozapine for the treatment-resistant schizophrenics. A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry, 45:789-796.
250. Kane, J.M., Woerner, M.G., Pollack, S., Safferman, A.Z., and Lieberman, J.A. (1993) Does clozapine cause tardive dyskinesia? J. Clin. Psychiatry, 54:327-330.
251. 2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: A PET study. Life Sci., 57:103-107.
252. 2 dopamine receptor binding differences of clozapine and haloperidol. J. Neural Transm., 86:163-173.
253. 1-receptor antagonist SCH 39166 in schizophrenic patients. Eur. Psychiatry, 9 (suppl.1):55.
254. Karoum, F., and Egan, M.F. (1992) Dopamine release and metabolism in the rat frontal cortex, nucleus accumbens, and striatum: A comparison of acute clozapine and haloperidol. Eur. J. Pharmacol., 105:703-707.
255. Karoum, F., Chrapusta, S.J., and Egan, M.F. (1994) 3-methoxytyramine is the major metabolite of released dopamine in the rat frontal cortex: Reassessment of the effects of antipsychotics on the dynamics of dopamine release and metabolism in the frontal cortex, nucleus accumbens, and striatum by a simple two pool method. J. Neurochem., 63:972-979.
256. 3 receptors. Psychopharmacology (Berlin), 116:464-468.
257. Kehr, W. (1976) 3-methoxytyramine as an indicator of impulse-induced dopamine release in rat brain in vivo. Naunyn Schmiedeberg, Arch. Pharmacol., 293:209-215.
258. Kelland, M.D., Freeman, A.S., and Chiodo, L.A. (1989) Chloral hydrate anesthesia alters the responsiveness of identified midbrain dopamine neurons to dopamine agonist administration. Synapse, 3:30-37.
259. Kelland, M.D., Chiodo, L.A., and Freeman, A.S. (1990) Anesthetic influences on the basal activity and pharmacological responsiveness of nigrostriatal dopamine neurons. Synapse, 6:207-209.
260. Kelly, P.H., and Moore, K.E. (1976) Selective 6-OHDA-induced destruction of mesolimbic dopamine neurons: Abolition of psychostimulant-induced locomotor activity. Eur. J. Pharmacol., 40.45-56.
261. Kelly, P.H., and Moore, K.E. (1977) Mesolimbic dopamine neurons: Effects of 6-hydroxydopamine-induced destruction and receptor blockade on drug-induced rotation of rats. Psychopharmacology (Berlin), 55:35-41.
262. 2C/2B receptor antagonist. Br. J. Pharmacol., 111:797-802.
263. 3H]acetylcholine from rat striatal slices. Neuroscience, 11:205-210.
264. Kilts, C.D., Andersen, C.M., Bissette, G., Ely, T.D., and Nemeroff, C.B. (1988) Differential effects of antipsychotic drugs on the neurotensin concentration of discrete rat brain nuclei. Biochem. Pharmacol., 37:1547-1554.
265. Kim, J.S., Kornhuber, J., Schmid-Burgh, W., and Holzmuller, B. (1980) Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosi. Lett., 20: 379-382.
266. Kimmel, S.E., Calabrese, J.R., Woyshville, M.J., and Meltzer, H.Y. (1994) Clozapine in treatment-refractory mood disorders. J. Clin. Psychiatry [Suppl.], 55:91-93.
267. Kinon, B.J. and Liebermann, J.A. (1996) Mechanisms of action of atypical antipsychotic drugs: A critical analysis. Psychopharmacology (Berlin), 124:2-34.
268. Kobeyashi, R.M., Fields, J.X., Hruska, R.E., Beaumont, and Yamamura, H.I. (1978) Brain neurotransmitter receptors and chronic antipsychotic drug treatment: A model for tardive dyskinesia. In: Animal Models in Psychiatry. I. Hanin and E. Usdin, eds. Pergamon Press, New York, pp. 405-409.
269. 3H-spiperone binding in the rat brain. Relation to blockade of apomorphine induced hyperactivity and stereotypies. J. Neural Transm., 52:163-173.
270. Kristensen, J.D., Svensson, B., and Gordh, T. (1992) The NMDA receptor antagonist CPP abolishes neurogenic "wind-up pain" after intrathecal administration in humans. Pain, 51:249-253.
271. 2C receptor density in the rat choroid plexus: Comparison with haloperidol. J. Pharmacol. Exp. Ther., 264:1262-1267.
272. 1C receptor antagonists. Eur. J. Pharmacol., 245:179-182.
273. 1C receptor-mediated phosphoinositide hydrolysis in the rat choroid plexus after chronic treatment with clozapine. Eur. J. Pharmacol., 255:91-97.
274. 2C. receptors in the rat choroid plexus after acute clozapine treatment. Eur. J. Pharmacol., 269:201-208.
275. 4 receptors in rat frontal cortex. J. Neural Transm., 101:231-235.
276. Laduron, P.M., and Leysen, J.E. (1978) Is the low incidence of extrapyramidal side-effects of antipsychotics associated with antimuscarinic properties? J. Pharm. Pharmacol., 30:120-122.
277. Lahti, R.A., Evans, D.L., Stratman, N.C., and Figur, L.M. (1993) Dopamine D4 versus D2 receptor selectivity of dopamine receptor antagonsits: Possible therapeutic implications. Eur. J. Pharmacol., 236:483-486.
278. Lahti, A.C., Holcomb, H.H., Medoff, D.R., and Taminga, C.A. (1995) Ketamine activates psychosis and alters limbic blood flow in schizophrenia. Neuroreport, 6:869-872.
279. Landwehrmeyer, B., Mengod, G., and Palacios, J.M. (1993) Differential visualization of dopamine D2 and D3 receptor sites in rat brain. A comparative study using in situ hybridization histochemistry and ligand binding autoradiography. Eur. J. Neurosci., 5:145-153.
280. 1-noradrenergic receptors demonstrated by in vivo voltammetry. Brain Res., 460:398-401.
281. 3H]zacopride as radioligands. Synapse, 10:271-278.
282. 3H]3-(3-hydroxyphenyl)-N-(1-propyl)piperidine. Proc. Natl. Acad. Sci. U.S.A., 81:4983-4987.
283. Leander, J.D. (1983) Interactions of clozapine, thioridazine and mezilamine with oxotremorine on schedule-controlled responding. Psychopharmacology (Berlin) 80:29-30.
284. 2) receptor numbers in the rat brain. Psychiatry Res., 12:277-285.
285. Le Fur, G., Burgevin, M.-C., Malgouris, C., and Uzan, A. (1979) Differential effects of typical and atypical neuroleptics on alpha-noradrenergic and dopaminergic postsynaptic receptors. Neuropharmacology, 18:591-594.
286. Le Fur, G., Guilloux, F., and Uzan, A. (1980) In vivo blockade of dopaminergic receptors from different rat brain regions by classical and atypical neuroleptics. Biochem. Pharmacol., 39:267-270.
287. 1A receptors. Eur. J. Pharmacol., 260:79-83.
288. 3 receptors. Synapse, 14:90-95.
289. 2-like dopamine receptors in rat brain. J. Pharmacol. Exp. Ther., 262:929-935.
290. 3H]hydroxy-N,N-di-n-propyl-2-aminotetralin. Proc. Natl. Acad. Sci. U.S.A., 89:8155-8159.
291. Lew, M.F., and Waters, C.H. (1993) Clozapine treatment of parkinsonism with psychosis. J. Am. Geriatr. Soc., 41:669-671.
292. Leysen, J.E., Niemegeers, C.J.E., Tollenaere, J.P., and Laduron, P.M. (1978) Serotonergic component of neuroleptic receptors. Nature, 272:168-171.
293. 2 receptor binding sites. Binding properties, brain distribution and functional role. Mol. Pharmacol., 21:301-314.
294. Leysen, J.E., Gommeren, W., Eens, A., De Courcelles, D., Stoof, J.C., and Janssen, P.A.J. (1988) Biochemical profile of risperidone, a new antipsychotic. J. Pharmacol. Exp. Ther., 247:661-670.
295. 2 receptors. Psychopharmacology (Berlin), 112:40-54.
296. 2-dopaminergic receptors in the primate cerebral cortex. Proc. Natl. Acad. Sci. U.S.A., 91:4353-4356.
297. Lidsky, T.I., Yablonsky-Alter, E., Zuck, L., and Banerjee, S.P. (1993) Anti-glutamatergic effect of clozapine. Neurosci. Lett., 163:155-158.
298. Lidsky, T.I., Yablonsky-Alter, E., Zuck, L., and Banerjee, S.P. (1995) "Antipsychotic drugs" mechanisms of action: Interactions at the NMDA receptor. Soc. Neurosci. Abstr., 21:1705.
299. Lieberman, J.A., Kane, J.M., and Johns, C.A. (1989) Clozapine: Guidelines for clinical management. J. Clin. Psychiatry, 50:329-338.
300. Lieberman, J.A., Johns, C., and Pollack, S. (1991) Effects of clozapine on amine metabolites in cerebrospinal fluid of schizophrenic patients. In: Schizophrenia Research. C.A. Tamminga and S.C. Schultz, eds. Raven Press, New York, pp. 341-349.
301. 2 antagonists on haloperidol-induced dyskinesias in squirrel monkeys: No evidence for reciprocal 5-HT-dopamine interaction. Psychopharmacology (Berlin), 97:456-461.
302. 3H]spioroperidol in calf caudate. J. Pharmacol. Exp. Ther., 212:462-468.
303. Lindgren, S. (1987) Lack of effects of apomorphine, haloperidol and clozapine on the synthesis and utilization of brain GABA. J. Neural Transm., 69:47-65.
304. 2 antagonist, augments fluphenazine in schizophrenic patients: A pilot study. J. Clin. Psychopharmacol., 13:264-267.
305. Ljungberg, T., and Ungerstedt, U. (1979) Evidence that the different properties of haloperidol and clozapine are not explained by differences in anticholinergic potency. Psychopharmacology (Berlin), 60:303-307.
306. Ljungberg, T., and Ungerstedt, U. (1985) A rapid and simple behavioural screening method for simultaneous assessment of limbic and striatal blocking effects of neuroleptic drugs. Pharmacol. Biochem. Behav., 23:479-485.
307. 3H]gamma-aminobutyric acid (GABA) binding in the human brain. Brain Res., 163:77-87.
308. Lloyd, K.G., and Hornykiewicz, O. (1977) Effect of chronic neuroleptic or L-DOPA administration on GABA levels in the rat substantia nigra. Life Sci., 21:1489-1496.
309. Lloyd, K.G., Shibuya, M., Davidson, L., and Hornykiewicz, O. (1977) Chronic neuroleptic therapy: Tolerance and GABA systems. Adv. Biochem. Psychopharmacol., 16:409-415.
310. 18FESP. Biol. Psychiatry [Suppl.], 165:166.
311. Lundberg, T., Lindstrom, L.H., Hartvig, P., Eckernas, S.-A., Ekblom, B., Lundqvist, H., Fasth, K.J., Gullberg, P., and Langstrom, B. (1989) Striatal and frontal cortex binding of 11-C-labelled clozapine visualized by positron emission tomography (PET) in drug-free schizophrenics and healthy volunteers. Psychopharmacology (Berlin), 99:8-12.
312. MacGibbon, G.A., Lawlor, P.A., Bravo, R., and Dragunow, M. (1994) Clozapine and haloperidol produce a differential pattern of immediate early gene expression in rat caudate-putamen, nucleus accumbens, lateral septum and islands of Calleja. Mol. Brain Res., 23:21-32.
313. Machida, C.A., Searles, R.P., Nipper, V., Brown, J.A., Kozell, L.B., and Neve, K.B. (1992) Molecular cloning and expression of the rhesus macaque D1 dopamine receptor. Mol. Pharmacol., 41:652-659.
314. 3 receptor expressed in transfected cell lines. Eur. J. Pharmacol., 266:79-85.
315. Maggi, A., Cattabeni, F., Bruno, F., and Racagni, G. (1977) Haloperidol and clozapine: Specificity of action on GABA in the nigrostriatal system. Brain Res., 133:382-385.
316. Mahadik, S.P., Laev, H., Korenovsky, A., and Karpiak, S.E. (1988) Haloperidol alters rat CNS cholinergic system: Enzymatic and morphological analyses. Biol. Psychiatry, 24:199-217.
317. Maidment, N.T., and Marsden, C.A. (1987a) Acute administration of clozapine, thioridazine and metoclopramide increases extracellular DOPAC and decreases extracellular 5-HIAA, measured in rat nucleus accumbens and striatum of the rat using in vivo voltammetry. Neuropharmacology, 26:187-193.
318. Maidment, N.T., and Marsden, C.A. (1987b) Repeated atypical neuroleptic administration: Effects on central dopamine metabolism monitored by in vivo voltammetry. Eur. J. Pharmacol., 136:141-149.
319. 3H]gamma-hydroxybutyrate binding by benzamide neuroleptics and prochlorperazone but not by other antipsychotics. Eur. J. Pharmacol., 256:211-214.
320. Maj, J., Sowinska, H., Baran, L., and Palider, W. (1974) The central action of clozapine. Pol. J. Pharmacol. Pharm., 26:425-435.
321. 3 receptors. Mol. Pharmacol. 43:749-754.
322. Mao, C.C., Marco, E., Revuelta, A., Bertilsson, L., and Costa, E. (1977) The turnover rate of gamma-aminobutyric acid in the nuclei of telencephalon: Implications in the pharmacology of antipsychotics and of a minor tranquilizer. Biol. Psychiatry, 12:359-371.
323. Marco, E., Mao, C.C., Cheney, D.L., Revuelta, A., and Costa, E. (1976) The effect of antipsychotics on the turnover rate of GABA and acetylcholine in rat brain nuclei. Nature, 264:363-365.
324. Marco, E., Mao, C.C., Revuelta, A., Peralta, E., and Costa, E. (1978) Turnover rates of α-aminobutyric acid in substantia nigra, n. caudatus, globus pallidus and n. accumbens of rats injected with cataleptogenic and non-cataleptogenic antipsychotics. Neuropharmacology, 12:589-596.
325. Marwah, J., and Aghajanian, G.K. (1982) Typical and atypical neuroleptics are potent antagonists at α-adrenoceptors of the dorsal lateral geniculate nucleus. Naunyn Schmiedebergs Arch. Pharmacol., 321:32-37.
326. Marwah, J., Hoffer, B.J., Geller, H.M., and Freedman, R. (1981) Electrophysiologic interactions of antipsychotic drugs with central noradrenergic pathways. Psychopharmacology (Berlin), 73:126-133.
327. 1A receptors in human brain tissue. Eur. J. Pharmacol., 221:397-398.
328. 2 receptor density in rat cerebral cortex. Life Sci., 45:1397-1406.
329. 2 receptor occupation by typical and atypical antipsychotic drugs. J. Pharmacol. Exp. Ther., 265:498-508.
330. Matthysse, S. (1973) Antipsychotic drug actions: A clue to the neuropathology of schizophrenia? Fed. Proc., 32:200-205.
331. Matz, R., Rick, W., Oh, D., Thompson, H., and Gershon, S. (1974) Clozapine - A potential antipsychotic agent without extrapyramidal manifestations. Curr. Ther. Res., 16:687-695.
332. McMillen, B.A. (1981) Comparative effects of classical and atypical antipsychotic drugs with a non-amphetamine stimulant on rat brain dopamine metabolism. J. Pharm. Pharmacol., 33:544-546.
333. McMillien, B.A., and Shore, P.A. (1978) Comparative effects of clozapine and α-adrenoceptor blocking drugs on regional noradrenaline metabolism in rat brain. Eur. J. Pharmacol., 52:225-230.
334. 3H]flunitrazepam by the atypical neuroleptic, clozapine. Neuropharmacology, 26:265-269.
335. McQuade, R.D., Ford, D., Duffy, R.A., Chipkin, R.E., Iorio, L.C., and Barnett, A. (1988) Serotonergic component of SCH 23390: In vitro and in vivo binding analyses. Life Sci., 43:1861-1869.
336. Meco, G., Bedini, L., Bonifati, V., and Sonsini, U. (1989) Ritanserin in tardive dyskinesia: A double-blind crossover study versus placebo. Curr. Ther. Res., 46:884-894.
337. Mefford, I.N., Roth, K.A., Agren, H., and Barchas, J.D. (1988) Enhancement of dopamine metabolism in rat brain frontal cortex: A common effect of chronically administered antipsychotic drugs. Brain Res., 475:380-384.
338. Meltzer, H.Y. (1989) Clinical studies on the mechanism of action of clozapine: The dopamine serotonin hypothesis of schizophrenia. Psychopharmacology [Suppl.] (Berlin), 99:18-27.
339. Meltzer, H.Y. (1992) Treatment of the neuroleptic non-responsive schizophrenic patient. Schizoph. Bull., 17:263-287.
340. Meltzer, H.Y., and Nash, J.F. (1991) VII. Effects of antipsychotic drugs on serotonin receptors. Pharmacol. Rev., 43:587-604.
341. Meltzer, H.Y., and Stahl, S.M. (1976) The dopamine hypothesis of schizophrenia: A review. Schizophr. Bull., 2:19-76.
342. 2 pKi values. J. Pharmacol. Exp. Ther., 251:238-246.
343. Meltzer, H.Y., Chai, B.L., Thompson, P.A., and Yamamoto, B.K. (1994) Effects of scopolamine on the efflux of dopamine and its metabolites after clozapine, haloperidol or thioridazine. J. Pharmacol. Exp. Ther., 268:1453-1461.
344. Meltzer, L.T., Christoffersen, C.L., Heffner, T.G., Freeman, A.S., and Chiodo, L.A. (1989) CI-943, a potential antipsychotic agent. III. Evaluation of effects on dopamine neuronal activity. J. Pharmacol. Exp. Ther. 251:123-130.
345. 1-adrenergic agonist. Life Sci., 43:1791-1804.
346. 1-adrenergic agonists. Psychopharmacology (Berlin), 101:67-72.
347. Merchant, K.M., and Drosa, D.M. (1993) Differential induction of neurotensin and c-fos gene expression by typical versus atypical antipsychotic drugs. Proc. Natl. Acad. Sci. U.S.A., 90:3447-3451.
348. Merchant, K.M., Dobner, P.R., and Dorsa, D.M. (1992) Differential effects of haloperidol and clozapine on neurotensin/neuromedin N gene transcription in rat neostriatum. J. Neurosci., 12:652-663.
349. Merchant, K.M., Dobie, D.J., Filloux, F.M., Totzke, M., Aravagiri, M., and Dorsa, D.M. (1994) Effects of chronic haloperidol and clozapine treatment on neurotensin and c-fos mRNA in rat neostriatal subregions. J. Pharmacol. Exp. Ther., 271:460-471.
350. Mercugliano, M., Saller, C.F., Salama, A.I., U'Prichard, D.C., and Chesselet, M.F. (1992) Clozapine and haloperidol have differential effects on glutamic acid decarboxylase mRNA in the pallidal nuclei of the rat. Neuropsychopharmacology, 6:179-187.
351. Mereu, G., Lilliu, V., Vargiu, P., Muntoni, A.L., Diana, M., and Gessa, G.L. (1995) Depolarization inactivation of dopamine neurons: An artifact? J. Neurosci., 15:1144-1149.
352. Meshul, C.K., Janowsky, A., Casey, D.E., Stallbaumer, R.K., and Taylor, B. (1992) Effect of haloperidol and clozapine on the density of "perforated" synapses in caudate, nucleus accumbens, and medial prefrontal cortex. Psychopharmacology (Berlin), 106:45-52.
353. Miller, R.J., and Hiley, C.R. (1974) Antimuscarinic properties of neuroleptics and drug induced parkinsonism. Nature, 248:596-597.
354. Miller, R.J., and Hiley, C.R. (1976) Anti-dopaminergic and anti-muscarinic effects of dibenzodiazepines: Relationship to drug-induced parkinsonism. Naunyn Schmiedebergs Arch. Pharmacol., 292:289-293.
355. Minabe, Y.M., Ashby, C.R., Jr., and Wang, R.Y. (1991) The CCK-A receptor antagonist devazepide but not the CCK-B receptor antagonist L-365,260 reverses the effect of chronic clozapine and haloperidol on midbrain dopamine neurons. Brain Res., 549:151-154.
356. Moghaddam, B. (1994a) Preferential activation of cortical dopamine neurotransmission by clozapine: Functional significance. J. Clin. Psychiatry [Suppl.], 55:27-29.
357. Moghaddam, B. (1994b) Recent basic findings in support of excitatory amino acid hypothesis of schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry, 18:859-870.
358. Moghaddam, B., and Bunney, B.S. (1990) Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: An in vivo microdialysis study. J. Neurochem., 54:1755-1760.
359. Monsma, F.J., McVittie, L.D., Gerfen, C.R., Mahan, L.C., and Sibley, D.R. (1989) Multiple D2 dopamine receptors produced by alternative RNA splicing. Nature, 342:926-929.
360. Monsma, F.J., Shen, Y., Ward, R.P., Hamblin, M.W., and Sibley, D.R. (1993) Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Mol. Pharmacol., 43:320-327.
361. Moore, K.E., and Kelly, P.H. (1978) Biochemical pharmacology of mesolimbic and mesocortical dopaminergic neurons. In: Psychopharmacology: A Generation of Progress. M.A. Lipton, S. DiMascio, and K.F. Killam, eds. Raven Press, New York, pp. 221-234.
362. Moore, N.C., and Gershon, S. (1989) Which atypical antipsychotics are identified by screening tests? Clin. Neuropharmacol., 12:167-189.
363. Moore, S., and Kenyon, P. (1994) Atypical antipsychotics, clozapine and sulpiride do not antagonise amphetamine-induced stereotyped locomotion. Psychopharmacology (Berlin), 114:123-130.
364. Morgan, J.I., and Curran, T. (1989) Stimulus-transcription coupling in neurons: Role of cellular immediate-early genes. Trends Neurosci., 12:459-462.
365. Morgan, J.I., and Curran, T. (1991a) Stimulus-transcription coupling in the nervous system: Involvement of the inducible proto-oncogenes fos and jun. Annu. Rev. Neurosci., 14:421-451.
366. Morgan, J.I., and Curran, T. (1991b) Proto-oncogene transcription factors and epilepsy. Trends Pharmacol. Sci., 12:343-349.
367. Mueller, K. (1993) Locomotor stereotypy is produced by methylphenidate and amfonelic acid and reduced by haloperidol but not clozapine or thioridazine. Pharmacol. Biochem. Behav., 45:71-76.
368. 2 receptor-mediated function: Behavior indices. Eur. J. Pharmacol., 186:79-86.
369. Nash, J.F., Meltzer, H.Y., and Gudelsky, G.A. (1988) Antagonism of serotonin receptor mediated neuroendocrine and temperature response by atypical neuroleptics in the rat. Eur. J. Pharmacol., 151:463-469.
370. 2 receptors of brain. Neuropharmacology, 30:527-529.
371. Nestros, J.N. (1982) Benzodiazepine and GABA receptors are functionally related: Further electrophysiological evidence in vivo. Prog. Neuropsychopharmacol. Biol. Psychiatry, 5:417-420.
372. New, J.S., Yevich, J.P., Temple, D.L., Jr., New, K.B., Gross, S.M., Schlemmer, R.F., Jr., Eison, M.S., Taylor, M.S., and Riblet, L.A. (1988) Atypical antipsychotic agents: Patterns of activity in a series of 3-substituted 2-pyridinyl-1-piperazine derivatives. J. Med. Chem., 31:618-624.
373. 1A receptors. Neuropharmacology, 35:119-121.
374. Nguyen, T. V., Kosofsky, B.E., Birnbaum, R., Cohen, B.M., and Heyman, S.E (1992) Differential expression of c-Fos and Zif628 in rat striatum after haloperidol, clozapine and amphetamine. Proc. Natl. Acad. Sci. U.S.A., 89:4720-4274.
375. Nielsen, E.B (1988) Cholinergic mediation of the discriminative stimulus properties of clozapine. Psychopharmacology (Berlin), 94:115-118.
376. Niemegeers, C.J.E., and Janssen, P.A.J. (1979) A systematic study of the pharmacological activities on dopamine antagonists. Life Sci., 24:2201-2216.
377. Niemegeers, C.J.E., Awouters, F., Lenaerts, F.M., Vermeire, J., and Janssen, P.A.J. (1982) Prevention of physostigmine-induced lethality in rats. A pharmacological analysis. Arch. Int. Pharmacodyn., 259:153-165.
378. Nissbrandt, H., Sundstrom, E., Jonsson, G., Hjorth, S., and Carlsson, A. (1989) Synthesis and release of dopamine in rat brain: Comparison between substantia nigra pars compacta, pars reticulata, and striatum. J. Neurochem., 52:1170-1182.
379. Nomikos, G.G., Iurlo, M., Andersson, J.L., Kimura, K., and Svensson, T.H. (1994) Systemic administration of amperozide, a new atypical antipsychotic drug, preferentially increases dopamine release in the rat medial prefrontal cortex. Psychopharmacology (Berlin), 115:147-156.
380. 2 receptor occupancy in clozapine treated patients demonstrated by PET. Psychopharmacology (Berlin), 110:365-367.
381. 2 receptor occupancy in relation to clozapine serum concentration: A PET study of schizophrenic patients. Am. J. Psychiatry, 152:1444-1449.
382. Nylanders, I., and Terenius, L. (1986) Chronic haloperidol and clozapine differentially affect dynorphin peptides and substance P in basal ganglia of the rat. Brain Res., 380:39-41.
383. Oakley, N.R., Hayes, A.G., and Sheehan, M.J. (1991) Effect of typical and atypical neuroleptics on the behavioral consequences of activation by muscimol of mesolimbic and nigro-striatal dopaminergic pathways in the rat. Psychopharmacology (Berlin), 105:204-208.
384. O'Connor, W.T., Drew, K.L., and Ungerstedt, U. (1989) Differences in dopamine released and metabolism in rat striatal subregions following acute clozapine using in vivo microdialysis. Neurosci. Lett., 98:211-216.
385. O'Dell, S.J., Hoste, G.J., Widmark, C.B., Shapiro, R.M., Potkin, S.G., and Marshall, J.F. (1990) Chronic treatment with clozapine or haloperidol differentially regulates dopamine and serotonin receptors in rat brain. Synapse, 6:146-153.
386. O'Donnell, P., and Grace, A.A. (1993) Dopaminergic modulation of dye coupling between neurons in the core and shell regions of the nucleus accumbens. J. Neurosci., 13:3456-3471.
387. Ogren, S.-O., Hall, H., and Kohler, C. (1978) Studies on the stereoselective dopamine receptor blockade in the rat brain by rigid spiroamines. Life Sci., 23:1769-1774.
388. Olney, J.W., and Farber, N.B. (1994) Efficacy of clozapine compared with other antipsychotics in preventing NMDA antagonist neurotoxicity. J. Clin. Psychiatry [Suppl.], 55:43-46.
389. Oretti, R.O., Spurlock, G., Buckland, P.R., and McGuffin, P. (1994) Lack of effect of antipsychotic and antidepressant drugs on glutamate receptor mRNA levels in rat brains. Neurosci. Lett., 177:39-43.
390. Osborne, P.G., O'Connor, W.T., and Ungerstedt, U. (1991) Effect of varying the ionic concentration of a microdialysis perfusate on basal striatal dopamine levels in awake rats. J. Neurochem., 56:452-456.
391. Pagliusi, S., Chollet-Daemerius, A., Losberger, C., Mills, A., and Kawashima, E. (1993) Characterization of a novel exon within the D3 receptor gene giving rise to an mRNA isoform expressed in rat brain. Biochem. Biophys. Res. Commun., 194:465-471.
392. 1b receptor. Eur. J. Pharmacol., 267:85-93.
393. Pehek, E.A., and Yamamoto, B.K. (1994) Differential effects of locally administered clozapine and haloperidol on dopamine efflux in the rat prefrontal cortex and caudate-putamen. J. Neurochem., 63:2118-2124.
394. Pehek, E.A., Yamamoto, B.K., and Meltzer, H.Y. (1991) The effect of clozapine on dopamine, 5-HT and glutamate release in the rat medial prefrontal cortex. Schizophr. Res., 4:323.
395. 3H]quinuclidinyl benzilate binding in rats. Brain Res., 171:473-480.
396. Peroutka, S.J., and Snyder, S.H. (1980) Relationships of neuroleptic drug effects at brain dopamine, serotonin alpha-adrenergic, and histamine receptors to clinical potency. Am. J. Psychiatry, 137:1518-1522.
397. Peroutka, S.J., U'Prichard, D.C., Greenberg, D.A., and Snyder, S.H. (1977) Neuroleptic drug interactions with norepinephrine alpha receptor binding sites in rat brain. Neuropharmacology, 16:549-556.
398. 2-adrenergic receptor affinity states in bovine caudate nucleus. Eur. J. Pharmacol., 95:315-318.
399. Petersen, E.N. (1981) Pre- and postsynaptic α-adrenoceptor antagonism by neuroleptics in vivo. Eur. J. Pharmacol., 69:399-405.
400. Peuch, A.J., Simon, P., and Boissier, J.R. (1978) Benzamides and classical neuroleptics: Comparison of their actions using 6 apomorphine-induced effects. Eur. J. Pharmacol., 50:291-300.
401. Pickar, D., Owen, R.R., Litman, R.E., Konicki, E., Guiterres, R., and Rapaport, M.N. (1992) Clinical and biologic response to clozapine in patients with schizophrenia. Arch. Gen. Psychiatry, 49:345-353.
402. Ponzio, F., Achilli, G., Perego, C., and Algeri, S. (1981) Differential effects of certain dopaminergic drugs on the striatal concentration of dopamine metabolites, with special reference to 3-methoxytyramine. Neurosci. Lett., 27:61-67.
403. Povlsen, U.J., Noring, U., Laursen, A.L., Korsgaard, S., and Gerlach, J. (1986) Effects of serotonergic and anticholinergic drugs in haloperidol-induced dystonia in cebus monkeys. Clin. Neuropharmacol., 9:84-90.
404. Prinssen, E.P.M., Ellenbroek, B.A., and Cools, A.R. (1994) Combined antagonism of adrenoceptors and dopamine and 5-HT receptors underlies the atypical profile of clozapine. Eur. J. Pharmacol., 262:167-170.
405. Racagni, G., Cheney, D.L., Trabucchi, M., and Costa, E. (1976) In vivo actions of clozapine and haloperidol on the turnover rate of acetylcholine in rat striatum. J. Pharmacol. Exp. Ther., 196:323-332.
406. Ramirez, O.A., and Wang, R.Y. (1986) Locus coeruleus norepinephrine-containing neurons: Effects produced by acute and subchronic treatment with antipsychotic drugs and amphetamine. Brain Res., 362:165-170.
407. Rao, P.A., Pickar, D., Gejamn, P.V., Ram, A., Gershon, E.S., and Gerlenter, J. (1994) Allelic variation in the D4 dopamine receptor (DRD4) gene does not predict response to clozapine. Arch. Gen. Psychiatry, 51:912-917.
408. Rao, T.S., Cler, J.A., Oei, E.J., Iyengar, S., and Wood, P.L. (1990) Increased release of dopamine in vivo by BMY-14802: Contrasting pattern to clozapine. Neuropharmacology, 29:503-506.
409. Rao, T.S., Contreras, P.C., Cler, J.A., Emmett, M.R., Mick, S.J., Iyengar, S., and Wood, P.L. (1991) Clozapine attenuates N-methyl-D-aspartate receptor complex-mediated responses in vivo: Tentative evidence for a functional modulation by a noradrenergic mechanism. Neuropharmacology, 30:557-565.
410. 2 receptor binding affinity. Neuropsychopharmacology, 1:101-107.
411. Rebec, G.V., Bashore, T.R., Zimmerman, K.S., and Alloway, K.D. (1979) "Classical" and "atypical" antipsychotic drugs: Differential antagonism of amphetamine- and apomorphine-induced alterations of spontaneous neuronal activity in the neostriatum and nucleus accumbens. Pharmacol. Biochem. Behav., 11:529-538.
412. Rebec, G.V., Bashore, T.R., Zimmerman, K.A., and Alloway, K.D. (1980) Neostriatal and mesolimbic neurons: Dose-dependent effects of clozapine. Neuropharmacology, 19:281-288.
413. Rebec, G.V., Alloway, K.D., and Bashore, T.R. (1981) Differential actions of classical and atypical antipsychotic drugs on spontaneous neuronal activity in the amygdaloid complex. Pharmacol. Biochem. Behav., 14:49-56.
414. Rebec, G.V., Gelman, J., and Alloway, K.D. (1983) Cataleptogenic potency of the antipsychotic drugs is inversely correlated with neuronal activity in the amygdaloid complex of the rat. Pharmacol. Biochem. Behav., 19:759-763.
415. Reynolds, G.P. (1996) The importance of dopamine D4 receptors in the action and development of antipsychotic agents. Drugs, 51:7-11.
416. 2 receptors. Eur. J. Pharmacol., 89:325-326.
417. Richelson, E., and Nelson, A. (1984) Antagonism by neuroleptics of neurotransmitter receptors of normal human brain in vitro. Eur. J. Pharmacol., 103:197-204.
418. Rivest, R., and Marsden, C.A. (1991) Muscarinic antagonists attenuate the increase in accumbens and striatum dopamine metabolism produced by clozapine but not haloperidol. Br. J. Pharmacol., 104:234.
419. Robertson, G.S., and Fibiger, H.C. (1992) Neuroleptics increase c-Fos expression in the forebrain: Contrasting effects of haloperidol and clozapine. Neuroscience, 46:315-328.
420. Robertson, A., and MacDOnald, C. (1984) Atypical neuroleptics clozapine and thioridazine enhance amphetamine-induced stereotypy. Pharmacol. Biochem. Behav., 21:97-101.
421. Robertson, G.S., Matsumura, H., and Fibiger, H.C. (1994) Induction of Fos-like immunoreactivity as predictors of atypical antipsychotic activity. J. Pharmacol. Exp. Ther., 271:1058-1066.
422. 3 receptor in rat brain. Br. J. Pharmacol., 114:1523-1524.
423. 1C receptors. J. Pharmacol. Exp. Ther., 260:1361-1365.
424. 4 dopamine receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs. Psychopharmacology (Berlin), 120:365-368.
425. Roth, R.H. (1987) Biochemical correlates of the electrophysiological activity of dopaminergic neurons: Reflections on two decades of collaboration with electrophysiologists. In: Neurophysiology of Dopaminergic Systems - Current Status and Clinical Perspectives. L.A. Chiodo and A.S. Freeman, eds. Lakeshore Publishing Co., Detroit, pp. 187-203.
426. 7) activating cAMP formation. Proc. Natl. Acad. Sci. U.S.A., 90:8547-8551.
427. 2 dopaminergic agonists in rat striatum. Brain Res., 496:385-388.
428. Ruch, W., Asper, H., and Burki, H.R. (1975) Effect of clozapine on the metabolism of serotonin in rat brain. Psychopharmacologia (Berlin), 46:103-109.
429. Rudeberg, C., Urwyler, S., Schulthess, C., and Herrling, P.L. (1986) Biochemical and pharmacological effects of fluperlapine on noradrenaline and acetylcholine systems in some rodent, bovine and crustacean preparations. Naunyn Schmiedebergs Arch. Pharmacol., 332:357-363.
430. Rupard, J.H., de Paulis, T., Janowsky, A., and Smith, H.E. (1989) Sterically hindered 5,11-dicarbo analogues of clozapine as potential chiral antipsychotic agents. J. Med. Chem., 32:2261-2268.
431. Rupniak, N.M.J., Kilpatrick, G., Hall, M.D., Jenner, P., and Marsden, C.D. (1984) Differential alteration in striatal dopamine receptor sensitivity induced by repeated administration of clinically equivalent doses of haloperidol, sulpiride or clozapine in rats. Psychopharmacology (Berlin), 84:512-519.
432. Rupniak, N.M.J., Hall, M.D., Mann, S., Fleminger, S., Kilpatrick, G., Jenner, P., and Marsden, C.D. (1985) Chronic treatment with clozapine, unlike haloperidol, does not induce changes in striatal D-2 receptor function in the rat. Biochem. Pharmacol., 34:2755-2763.
433. 3H-flunitrazepam binding during continuous treatment of rats for up to 1 year with haloperidol, sulpiride or clozapine. J. Neural Transm., 68:113-125.
434. Safferman, A., Lieberman, J.A., Kane, J.M., Szymanski, S., and Kinon, B. (1993) Update on the clinical efficacy and side effects of clozapine. Psychopharmacol. Bull., 17:247-261.
435. Salami, P., Karlsson, T., and Ahlenius, S. (1994) Antagonism of SCH 23390 of clozapine-induced hypothermia in the rat. Eur. J. Pharmacol., 253:67-73.
436. Sailer, C.F., and Salama, A.I. (1986) 3-methoxytyramine accumulation: Effects of typical neuroleptics and various atypical compounds. Naunyn Schmiedebergs Arch. Pharmacol., 334:125-132.
437. Saller, C.F., Kraemer, L.D., Adamouage, L.A., and Salama, A.I. (1989) Dopamine receptor occupancy in vivo: Measurement using N-ethoxycarbonyl-2-ethoxy-1,2-dihydroguine (EEDQ). Life Sci., 45:917-929.
438. Sanchez, C., Arnt, J., Dragsted, N., Hyttel, J., Lembol, H.L., Meier, E., Perregaard, J., and Skarsfeldt, T. (1991) Neurochemical and in vivo profile of sertinodole, a limbic-selective neuroleptic compound. Drug Dev Res., 22:239-250.
439. Sayers, A.C., Burki, H.R., Ruch, W., and Asper, H. (1975) Neuroleptic-induced hypersensitivity of striatal dopamine receptors in the rat as a model of tardive dyskinesias: Effects of clozapine, haloperidol, loxapine and chlorpromazine. Psychopharmacology (Berlin), 41:97-104.
440. Sayers, A.C., Burki, H.R., Ruch, W., and Asper, H. (1976) Anticholinergic properties of antipsychotic drugs and their relationship to extrapyramidal side effects. Psychopharmacology (Berlin), 51:15-27.
441. 3 receptor pharmacophore. Mol. Pharmacol., 36:505-511.
442. Schmidt, W.J. (1986) Intrastriatal injection of DL-2-amino-5-phosphonovaleric acid (AP-5) induces sniffing stereotypy that is antagonized by haloperidol and clozapine. Psychopharmacology (Berlin), 90:123-130.
443. Schmidt, W.J. (1991) The glutamatergic system as a target of antipsychotic drug drug action. In: Animal Models in Psychopharmacology, Advances in Pharmacological Sciences. B. Olivier, J. Mos, and J.L. Slagen, eds. Birkhauser, Basel, pp. 289-293.
444. Schmidt, W.J., and Volz, T.L. (1992) Clozapine-like discriminative stimulus effects of N-methyl-D-asparate (NMDA). J. Psychopharmacol., [Suppl.], 264.
445. Schmidt, W.J., Krahling, H., and Ruhland, M. (1987) Antagonism of AP-5- and amphetamine-induced behaviour by timelotem as compared with clozapine and haloperidol. Life Sci., 41:1909-1914.
446. 6 receptor-like profile stimulating adenyl cyclase activity in pig caudate membranes. Naunyn Schmiedebergs Arch. Pharmacol., 350:356-360.
447. Schotte, A., Janssen, P.F.M., Megens, A.A.H.P., and Leysen, J.E. (1993) Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured by quantitative autoradiography. Brain Res., 631:191-202.
448. Schotte, A., Jansson, P.F.M., Gommeren, W., Luyten, W.H.M.L., Van Gompel. P., Lesage, A.S., De Loore, K., and Leysen, J.E. (1996) Risperidone compared with new and reference antipsychotic drugs: In vitro and in vivo receptor binding. Psychopharmacology (Berlin), 124:57-73.
449. Schreiber, R., Brocco, M., and Millian, M.J. (1994) Blockade of the discriminative stimulus effects of DOI by MDL 100,907 and the "atypical" antipsychotics, clozapine and risperidone. Eur. J. Pharmacol., 264:99-102.
450. Sebens, J.B., Koch, T., Ter Horst, G.J., and Korf, J. (1995) Differential Fos-protein induction in rat forebrain regions after acute and long-term haloperidol and clozapine treatment. Eur. J. Pharmacol., 273:175-182.
451. See, R.E., and Chapman, M.A. (1994) Chronic haloperidol, but not clozapine, produces altered oral movements and increased extracellular glutamate in rats. Eur. J. Pharmacol., 263:269-276.
452. See, R.E., Toga, A. W., and Ellison, G. (1990) Autoradiographic analysis of regional alterations in brain receptors following chronic administration and withdrawal of typical and atypical neuroleptics in rats. J. Neural Transm., 82:93-109.
453. Seeger, T.F., and Gardner, E.L. (1979) Enhancement of self-stimulation behavior in rats and monkeys after chronic neuroleptic treatment: Evidence for mesolimbic supersensitivity. Brain Res., 175:49-57.
454. Seeger, T.F., Thai, L., and Gardner, E.L. (1982) Behavioral and biochemical aspects of neuroleptic-induced dopaminergic supersensitivity: Studies with chronic clozapine and haloperidol. Psychopharmacology (Berlin), 76:182-187.
455. Seeman, P. (1992) Dopamine receptor sequences. Therapeutic levels of neuroleptics occupy D2, clozapine occupies D4. Neuropsychopharmacology, 7:261-284.
456. Seeman, P., and Ulpian, C. (1983) Neuroleptics have identical potencies in human brain limbic and putamen regions. Eur. J. Pharmacol., 94:145-148.
457. Seeman, P., and Van Tol, H.M. (1993) Dopamine receptor pharmacology. Curr. Opin. Neurol. Neurosurg., 6:602-608.
458. Seeman, P., Lee, T., Chau-Wong, M., Tedesco, J., and Wong, K. (1976) Antipsychotic drug doses and neuroleptic\dopamine receptors. Nature, 261:717-719.
459. Severson, J.A., Robinson, H.E., and Simpson, G.M. (1984) Neuroleptic-induced striatal dopamine receptor supersensitivity in mice: Relationship to dose and drug. Psychopharmacology (Berlin), 84:115-119.
460. Sharp, T., Zetterstrom, T., Ljungberg, T., and Ungerstedt, U. (1986) Effect of sulpiride on amphetamine-induced behaviour in relation to changes in spatial dopamine release. Eur. J. Pharmacol., 129:411-115.
461. Sherman, A.D., and Mott, J. (1984) Direct effect of neuroleptics on glutamate release. Neuropharmacology, 23:1253-1259.
462. 2A/2C antagonist, reverses direct dopamine agonist-induced inhibition of midbrain dopamine neurons. J. Pharmacol. Exp. Ther., 274:735-740.
463. Shibata, K., Haverstick, D.M., and Bannon, M.J. (1990) Tachykinin gene expression in rat limbic nuclei: Modulation by dopamine antagonists. J. Pharmacol. Exp. Ther., 255:388-392.
464. Shopsin, B.H., Klein, H., Aaronsom, M., and Collora, M. (1979) Clozapine, chlorpromazine, and placebo in newly hospitalized, acutely schizophrenic patients. A controlled, double-blind comparison. Arch. Gen. Psychiatry, 36:657-664.
465. Simpson, C.S., and Morris, B.J. (1994) Haloperidol and fluphenazine induce junB gene expression in rat striatum and nucleus accumbens. J. Neurochem., 63:1955-1961.
466. Singh, M.M., and Kay, S.R. (1979a) Therapeutic antagonism between anticholinergic agents and neuroleptics in schizophrenia. Neuropsychobiology, 5:74-86.
467. Singh, M.M., and Kay, S.R. (1979b) Therapeutic antagonism between anticholinergic antiparkinonian agents and neuroleptics in schizophrenia. Implications for a neuropharmacological model. Neuropsychobiology, 5:74-86.
468. Skarsfeldt, T. (1988) Differential effects after repeated administration with haloperidol, clozapine, thioridazine and tefludazine on SNC and VTA dopaminergic neurones in rats. Life Sci., 42:1037-1044.
469. Skarsfeldt, T. (1992) Electrophysiological profile of the new atypical neuroleptic, sertindole, on midbrain dopamine neurons in rats: Acute and repeated treatments. Synapse, 10:25-33.
470. Skarsfeldt, T. (1994) Comparison of short-term administration of sertindole, clozapine and haloperidol on the inactivation of midbrain dopamine neurons in the rat. Eur. J. Pharmacol., 254:291-294.
471. 1-receptor blocking properties. Eur. J. Pharmacol., 125:333-340.
472. 1B-adrenoceptors. Eur. J. Pharmacol., 238:407-410.
473. Smith, R.C., and Davis, J.M. (1976) Behavioral evidence for supersensitivity after chronic administration of haloperidol, clozapine, and thioridazine. Life, Sci., 19:725-732.
474. Snyder, S.H., Greenberg, D., and Yamamura, H.I. (1974) Antischizophrenic drugs and brain cholinergic receptors: Affinity for muscarinic sites predicts extrapyramidal effects. Arch. Gen. Psychiatry, 31:58-61.
475. 2C receptor gene. Neuroreport, 7:169-172.
476. 3) as a target for neuroleptics. Nature, 347:146-151.
477. 2 receptor. Eur. J. Pharmacol., 225:331-337.
478. Somoza, E., Franco, C., Lavina, M., and Fuentes, J.A. (1981) Clozapine inhibition of met-enkephalin binding to synaptosome-enriched fractions of whole brain and hippocampus. Neurochem. Res., 6:413-424.
479. Somoza, E., Bazan, E., and Galindo, A. (1982) Inhibition of Leuenkephalin binding by neuroleptics. Neuropsychobiology, 8: 297-303.
480. 2 receptor antagonist MDL 100907 as a putative atypical antipsychotic: Behavioral, electrophysiological and neurochemical studies. J. Pharmacol. Exp. Ther., 266:684-691.
481. Souto, M., Monti, J.M., and Altier, H. (1979) Effects of clozapine on the activity of central dopaminergic and noradrenergic neurons. Pharmacol. Biochem. Behav., 10:5-9.
482. A receptor blockers: Implications for psychiatry. Neurochem. Res., 18:787-793.
483. Stamford, J.A., Kruk, Z.L., and Millar, J. (1988) Actions of dopamine antagonists on stimulated striatal and limbic dopamine release: An in vivo voltammetric study. Br. J. Pharmacol., 94:924-932.
484. Stawarz, R.J., Hill, H., Robinson, S.E., Setler, P., Dingell, J.V., and Sulser, F. (1975) On the significance of the increase in homovanillic acid (HVA) caused by antipsychotic drugs in the corpus striatum and limbic forebrain. Psychopharmacologia (Berlin), 43:125-130.
485. Stevens, J.R. (1973) An anatomy of schizophrenia? Arch. Gen. Psychiatry, 29:177-189.
486. Stille, G., Lauener, H., and Eichenberger, E. (1971) The pharmacology of 8-chloro-11-(4-methyl-1-piperazynl)-5H-dibenzo[b,e] [1,4]diazepine (clozapine). Farmaco, 26:603-625.
487. Stockmeier, C.A., DiCarlo, J.J., Zhang, Y., Thompson, P., and Meltzer,
488. Sulser, F., and Robinson, S.E. (1978) Clinical implications of pharmacological differences among antipsychotic drugs with particular emphasis on biochemical central synaptic adrenergic mechanisms. In: Psychopharmacology: A Generation of Progress. M.A. Lipton, A. DiMascio, and K.F. Killam, eds. Raven Press, New York, pp. 943-954.
489. 2 receptor occupancy. Neuropsychopharmacology, 12:57-64.
490. Sunahara, R.K., Guan, H.C., O'Dowd, B.F., Seeman, P., Laurier, L.G., Ng, G., George, S.R., Torchia, J., Van Toi, H.H.M., and Niznik, H.B. (1990) Human dopamine D1 receptor encoded by an intronless gene on chromosome 5. Nature, 347:80-83.
491. 1. Nature, 350:614-618.
492. Suppes, T., and Pinnock, R.D. (1987) Sensitivity of neuronal dopamine response in the substantia nigra and ventral tegmentum to clozapine, metoclopramide and SCH 23390. Neuropharmacology, 26:331-337.
493. Svartengren, J., and Celander, M. (1994) The limbic functional selectivity of amperozide is not mediated by dopamine D2 receptors as assessed by in vitro and in vivo binding. Eur. J. Pharmacol., 254:73-81.
494. Svendsen, O., Amt, J., Boeck, V., Bogeso, K.P., Christensen, A.V., Hyttel, J., and Larsen, J.-J. (1986) The neuropharmacological profile of tefludazine, a potential antipsychotic drug with dopamine and serotonin receptor antagonistic effects. Drug Dev. Res., 7:35-47.
495. Svensson, T.H., Mathe, J.M., Andersson, J.L., Nomikos, G.G., Hildebrand, B.E., and Marcus, M. (1995) Mode of action of atypical neuroleptics in relation to the phencyclidine model of schizophrenia: Role of 5-HT2 receptor and alpha 1-adrenoceptor antagonism. J. Clin. Psychopharmacol. [Suppl.], 15:11-18.
496. Szewczak, M.R., Cornfeldt, M.L., Dunn, R.W., Wilker, J.C., Geyer, H.M., Glamkowski, E.J., Chiand, Y., and Fielding, S. (1987) Pharmacological evaluation of HP 370, a potential atypical antipsychotic agent: 1. In vivo profile. Drug Dev. Res., 11:157-168.
497. Szymanski, S., Lieberman, J., Pollack, S., Munne, R., Safferman, A., Kane, J., Kronig, M., and Cooper, T. (1993) The dopamine-serotonin relationship in clozapine response. Psychopharmacology (Berlin), 112:85-89.
498. Tandon, R., and Kane, J.M. (1993) Neuropharmacologic basis for clozapine's unique profile. Arch. Gen. Psychiatry, 50:158-159.
499. Tang, L., Todd, R.D., Heller, A., and O'Malley, K.L. (1993) Pharmacological and functional characterization of D2, D3 and D4 dopamine receptors in fibroblasts and dopaminergic cell lines. J. Pharmacol. Exp. Ther., 268:495-502.
500. Tarsy, D., and Baldessarini, R.J. (1977) The pathophysiological basis of tardive dyskinesia. Biol. Psychiatry, 12:431-450.
501. Tayar, N., Kilpatrick, G.J., Van De Waterbeemd, H., Testa, B., Jenner, P., and Marsden, C.D. (1988) Interaction of neuroleptic drugs with rat striatal D-1 and D-2 dopamine receptors: A quantitative structure-affinity relationship study. Eur. J. Med. Chem., 23:173-182.
502. Tepper, J.M., Crese, I., and Schwartz, D.H. (1991) Stimulus-evoked changes in neostriatal dopamine levels in awake and anesthetized rats as measured by microdialysis. Brain Res., 559:283-292.
503. Terai, M., Usuda, S., Kuroiwa, I., Noshiro, O., and Maeno, H. (1983) Selective binding of YM-09151-2, a new potent neuroleptic, to D2-dopaminergic receptors. Jpn. J. Pharmacol., 33:749-755.
504. Thurkauf, A., Yuan, J., Chen, X., Wasley, J.W., Meade, R., Woodruff, K.H., Huston, K., and Ross, P.C. (1995) 1-Phenyl-3-(aminoethyl) pyrroles as potential antipsychotic agents. Synthesis and dopamine receptor binding. J. Med. Chem., 38:4950-4952.
505. Tiedtke, P.I., Bishoff, C., and Schmidt, W.J. (1990) MK-801-induced stereotypy and its antagonism by neuroleptic drugs. J. Neural Transm., 81:173-182.
506. Tschanz, J.T., and Rebec, G.V. (1989) Atypical antipsychotic drugs block selective components of amphetamine-induced stereotypy. Pharmacol. Biochem. Behav., 31:519-522.
507. Ulas, J., Nguyen, L., and Cotman, C.W. (1993) Chronic haloperidol treatment enhances binding to NMDA receptors in rat cortex. Neuroreport, 4:1049-1051.
508. Uretsky, N.J., and Iversen, L.L. (1970) Effects of 6-hydroxydopamine on catecholamine containing neurons in the rat brain. J. Neurochem., 12:269-278.
509. Uzan, A., Le Fur, G., Mitrani, N., Kabouche, M., and Donadieu, A.-M. (1978) Effects on striatal and mesolimbic dopamine systems of a new potential antipsychotic drug mezilamine with weak cataleptogenic properties. Life Sci., 23:261-274.
510. 4 receptor with high affinity for the antipsychotic clozapine. Nature, 350:610-614.
511. Van Tol, H.M., Wu, C.M., Guan, H.-C., Ohara, K., Bunzow, J.R., Civelli, O., Kennedy, J., Seeman, P., Niznik, H.B., and Jovanovic, V. (1992) Multiple dopamine D4 receptor variants in the human population. Nature, 358:149-152.
512. Vasse, M., and Protais, P. (1988) Increased grooming behavior is induced by apomorphine in mice treated with discriminative benzamide derivatives. Eur. J. Pharmacol., 156:1-11.
513. Vayer, P., Mandel, P., and Maitre, M. (1987) Gamma-hydroxybutyrate: A possible neurotransmitter. Life Sci., 41:1547-1557.
514. Verma, A., and Kulkarni, S.K. (1993) Modulation of MK-801 response by dopaminergic agents in mice. Psychopharmacology (Berlin), 107:431-436.
515. 3 receptorantagonist itasetron (DAU6215) on (+)-N-allylnormetazocine-induced dopamine release in the nucleus accumbens and in the corpus striatum of the rat: An in vivo study. J. Pharmacol. Exp. Ther., 275:358-367.
516. Von Stralendorff, V.B., Ackenheil, M., and Zimmerman, J. (1976) Akute und chronische Wirkung von Capipramin, Clozapin, Haloperidol und Sulpirid auf den stoffwechsel biogener Amine in Rattengehirn. Arzneimittelforschung, 26:1096-1098.
517. Wadenberg, M.-L., Alhenius, S., and Svensson, T.H. (1993) Potency mismatch for behavioral and biochemical effects by dopamine receptor antagonist: Implications for the mechanism of action of clozapine. Psychopharmacology (Berlin), 110:273-279.
518. Waldmeier, P.C., and Maitre, L. (1976a) Clozapine: Reduction of the initial dopamine turnover increase by repeated treatment. Eur. J. Pharmacol., 38:197-203.
519. Waldmeier, P.C., and Maitre, L. (1976b) On the relevance of preferential increases of mesolimbic versus striatal dopamine turnover for the prediction of antipsychotic activity of psychotropic drugs. J. Neurochem., 27:589-597.
520. 2-adrenergic receptor subtypes in the brain. Pharmacol. Biochem. Behav., 41:267-273.
521. 2 receptors of normal human brain in vitro. Eur. J. Pharmacol., 143:279-282.
522. Wang, R.Y., and Arvanov, V.L. (1996) The potentiation of NMDA-induced inward current by antipsychotics in cortical cells. Neurosci. Abst., 22:65.
523. 3-like receptors in the action of clozapine. J. Clin. Psychiatry [Suppl.], 55:23-26.
524. 3-like receptors. Behav. Neural Sci., 73:7-10.
525. Ward, K.M., Liston, D., Jones, S.B., and Zorn, S.H. (1994) The atypical antipsychotic clozapine is a potent agonist at human cholinergic muscarinic m4 receptors and an antagonist at ml, m2, m3 and m5 receptors. Soc. Neurosci. Abstr, 20:1637.
526. Ward, R.P., Hamblin, M.W., Lachowicz, J.E., Hoffman, B.J., Sibley, D.R., and Dorsa, D.M. (1995) Localization of serotonin subtype 6 receptor messenger RNA in the rat brain by in situ hybridization histochemistry. Neuroscience, 64:1105-1111.
527. 3 receptors in the cerebral cortex and superior cervical ganglion of the rat. Eur. J. Pharmacol., 182:465-472.
528. Westerink, B.H.C. (1985) Sequence and significance of dopamine metabolism in the rat brain. Neurochem. Int., 7:221-227.
529. Westerink, B.H.C., and Korf, J. (1975) Influence of drugs on striatal and limbic homovanillic acid concentration in the brain. Eur. J. Pharmacol., 33:31-40.
530. Westerink, B.H.C., and Korf, J. (1976) Regional rat brain levels of 3,4-dihydroxyphenylacetic acid and homovanillic acid: Concurrent fluorimetric measurement and influence of drugs. Eur. J. Pharmacol., 38:281-291.
531. Westerink, B.H.C., and Spaan, S. J. (1982) On the significance of endogenous 3-methoxytyramine for the effects of centrally acting drugs on dopamine release in the rat brain. J. Neurochem., 38:680-686.
532. Westphal, R.S., and Sanders-Bush, E. (1994) Reciprocal binding properties of 5-hydroxytryptamine type 2C receptor agonists and inverse agonists. Mol. Pharmacol., 46:937-942.
533. White, F.J., and Wang, R.Y. (1983) Differential effects of typical and atypical antipsychotic drugs on A9 and A10 dopamine neurons. Science, 221:1054-1057.
534. Weisel, F.-A., and Sedvall, G. (1975) Effect of antipsychotic drugs on homovanillic acid levels in striatum and olfactory tubercle of the rat. Eur. J. Pharmacol., 30:364-367.
535. Wiley, J.L. (1994) Clozapine's effect on phencyclidine-induced disruption of prepulse inhibition of the acoustic startle response. Pharmacol. Biochem. Behav., 49:1025-1028.
536. Wiley, J. L., and Porter, J.H. (1992) Serotonergic drugs do not substitute for clozapine in clozapine-trained rats in a two-lever drug discrimination procedure. Pharmacol. Biochem. Behav., 43:961-965.
537. Wilk, S., and Glick, S.D. (1976) Dopamine metabolism in the nucleus accumbens: The effect of clozapine. Eur. J. Pharmacol., 37:203-206.
538. Wilk, S., and Stanley, M. (1977) Perlapine and dopamine metabolism: Prediction of antipsychotic efficacy. Eur. J. Pharmacol., 41:65-72.
539. Wilk, S., and Stanley, M. (1978) Clozapine concentrations in brain regions: Relationship to dopamine metabolite increase. Eur. J. Pharmacol., 51:101-107.
540. Wilk, S., Watson, E., and Stanley, M.E. (1975) Differential sensitivity of two dopaminergic structures in rat brain to haloperidol and clozapine. J. Pharmacol. Exp. Ther., 195:265-270.
541. 2) receptors in the rat brain. Brain Res., 487:288-298.
542. Wise, L.D., Pattison, I.C., Butler, D.E., DeWald, H.A., Lewis, E.P., Lobbestael, S.J., Nordin, I.C., Popschel, B.P.H., and Coughenour, L.L. (1985) 1-[3-(diarylamino)propyl]piperidines and related compounds, potential antipsychotic agents with low cataleptogenic profiles. J. Med. Chem., 28:606-612.
543. Wood, P.L., and Altar, A. (1988) Dopamine release in vivo from nigrostriatal, mesolimbic and mesocortical neurons: Utility of 3-methoxytyramine measurements. Pharmacol. Rev., 40:163-207.
544. Worms, P., and Lloyd, K.G. (1979) Predictability and specificity of behavioral screening tests for neuroleptics. Pharmacol. Ther., 5:445-450.
545. Worms, P., Broekkamp, C.L.E., and Lloyd, K.G. (1983) Behavioral effects of neuroleptics. In: Neuroleptics: Neurochemical, Behavioral and Clinical Perspectives. J.T. Coyle and S.J. Enna, eds. Raven Press, New York, pp. 93-117.
546. Yamamoto, B.K., and Cooperman, M.A. (1994) Differential effects of chronic antipsychotic drug treatment on extracellular glutamate and dopamine concentrations. J. Neurosci., 14:4159-4166.
547. Yamamoto, B.K., Pehek, E.A., and Meltzer, H.Y. (1994) Brain region effects of clozapine on amino acid and monoamine transmission. J. Clin. Psychiatry [Suppl.], 55:8-14.
548. Youngren, K.D., Moghaddam, B., Bunney, B.S., and Roth, R.H. (1994) Preferential activation of dopamine overflow in prefrontal cortex produced by chronic clozapine treatment. Neurosci. Lett., 165:41-44.
549. Zeng, X.P., Le, F., Scarisbrick, I., and Richelson, E. (1995) Muscarinic m4 receptor agonism by atypical but not atypical antipsychotics. Soc. Neurosci. Abstr, 21:1707.
550. Zhang, S.-P., Connell, T.A., Price, T., Simpson, G.M., Zhou, L.-W., and Weiss, B. (1995) Continuous infusions of clozapine increases mu and delta opioid receptors and proenkephalin mRNA in mouse brain. Biol. Psychiatry, 37:496-503.
551. 4 receptor agonist. Eur. J. Pharmacol., 269:1-2.